

From the Department of Microbiology, Tumor and Cell Biology,  
Karolinska Institutet, Stockholm, Sweden and the Swedish Institute for  
Communicable Disease Control, Solna, Sweden

**EVALUATION OF HIV TESTING STRATEGIES AND  
MONITORING OF IMMUNE RESPONSES IN HIV-  
VACCINATED INDIVIDUALS IN TANZANIA**

Said Aboud



**Karolinska  
Institutet**

Stockholm 2011

All previously published papers were reproduced with permission from the publishers.

Published by Karolinska Institutet. Printed by Karolinska University Press

© Said Aboud, 2011

ISBN 978-91-7457-477-7

## ABSTRACT

This thesis describes studies on the evaluation of human immunodeficiency virus (HIV) enzyme-linked immunosorbent assays (ELISAs) and simple rapid HIV assays for use in HIV testing strategies in resource-limited settings and studies of HIV vaccine-induced immune responses. Peripheral blood mononuclear cell (PBMC) preparation techniques were also studied in preparation for use in the HIV vaccine trials.

The performance of two antibody ELISAs (Vironostika Uni-Form II plus O and Enzygnost anti-HIV-1/2 Plus) and two new diagnostic HIV antigen/antibody combination ELISAs (Murex and Vironostika HIV Uni-Form II antigen/antibody) was evaluated using 1380 serum samples from Tanzanian individuals (paper I). The sensitivity at initial testing was 100% for all assays except Vironostika Uni-Form II plus O which showed one false negative sample at initial testing but 100% sensitivity after repeat testing. The initial specificity was 99.8% for Enzygnost, 98.9% for each of the antigen/antibody ELISAs and 97.0% for Vironostika Plus O ELISA. An alternative confirmatory HIV testing strategy based on initial testing on any of the two antigen/antibody assays followed by testing of reactive samples on the Enzygnost anti-HIV-1/2 Plus assay gave 100% specificity (95% CI; 99.7-100%).

The performance of five simple rapid HIV antibody assays was evaluated using 1433 whole blood samples (paper II). The sensitivity at initial testing of Determine, SD Bioline and Uni-Gold was 100% while First Response and Stat-Pak had a sensitivity of 99.5% and 97.7%, respectively, which increased to 100% on repeat testing. The initial specificity of the Uni-Gold assay was 100% while the specificities were 99.6%, 99.4%, 99.6% and 99.8% for Determine, SD Bioline, First Response and Stat-Pak assays, respectively. An alternative confirmatory HIV testing strategy based on initial testing on SD Bioline followed by testing of reactive samples on the Determine gave 100% sensitivity (95% CI; 99.1-100) and 100% specificity (95% CI; 96-99.1) with Uni-Gold as tiebreaker for discordant results and was adopted as a national algorithm in Tanzania.

Standard Ficoll-Paque gradient (FIP) centrifugation, BD vacutainer cell preparation tube (CPT) and Greiner Bio-One LeucoSep tube techniques for PBMC preparation were evaluated (paper III). No differences in mean recovery or mean viability of fresh PBMCs were observed between FIP centrifugation and CPT techniques used in Stockholm. In Dar es Salaam, recovery and viability of PBMCs isolated by FIP technique was higher compared to CPT purified cells. LeucoSep cell separation gave a higher yield and viability than FIP cell separation. The cells purified by the different techniques at the two sites performed equally well in interferon-gamma (IFN- $\gamma$ ) enzyme-linked immunospot (ELISpot) assays.

In a phase 1 HIV-1 DNA prime MVA boost vaccine trial in Sweden (HIVIS01/02), HIV-specific lymphoproliferative responses were tested by a [3H]-thymidine uptake assay and a flow-cytometric assay using whole blood (FASCIA-WB) (paper IV). A FASCIA using PBMC (FASCIA-PBMC) was also employed (n=14). Two weeks after the HIV-MVA boost 35 of 38 (92%) vaccinees were reactive by the thymidine uptake assay. Thirty-two of 38 (84%) vaccinees were reactive by the CD4<sup>+</sup> T-cell FASCIA-WB, and 7 of 38 (18%) also exhibited CD8<sup>+</sup> T-cell responses. There was strong correlation between the proliferative responses measured by the thymidine uptake assay and CD4<sup>+</sup> T-cell FASCIA-WB ( $r=0.68$ ;  $P < 0.01$ ). Fourteen vaccinees were analyzed using all three assays. Ten of 14 (71%) and 11/14 (79%) demonstrated CD4<sup>+</sup> T-cell responses in FASCIA-WB and FASCIA-PBMC, respectively. CD8<sup>+</sup> T-cell reactivity was observed in 3/14 (21%) and 7/14 (50%) using the FASCIA-WB and FASCIA-PBMC, respectively. All 14 were reactive by the thymidine uptake assay. A FASCIA-PBMC, which allows simultaneous phenotyping, may be an option to the [3H] thymidine uptake assay for assessment of vaccine-induced T-cell proliferation, especially in isotope-restricted settings.

In the HIVIS03 phase I/II HIV vaccine trial in Tanzania, sixty HIV-uninfected volunteers randomised to three groups of 20, received DNA plasmid vaccine 1 mg intradermally (id) or 3.8 mg intramuscularly (im) or placebo using a needle-free injection device (paper V). DNA plasmids vectoring HIV-1 genes gp160 subtypes A, B, C; rev B; p17/p24 gag A, B and Rtmu B were given at weeks 0, 4 and 12. Recombinant MVA ( $10^8$  pfu) expressing HIV-1 Env, Gag, Pol of CRF01\_AE or placebo was administered im at month 9 and 21. The vaccines were well tolerated. Two weeks after the first HIV-MVA boost 35/35 (100%) vaccinees had IFN- $\gamma$  ELISpot responses; 35 (100%) to Gag and 31 (89%) to Env. Two to four weeks after the second HIV-MVA boost, 28/29 (97%) vaccinees had IFN- $\gamma$  responses. The id -primed recipients had significantly higher responses to Env than im recipients after HIV-MVA boost. Intracellular cytokine staining for Gag-specific IFN- $\gamma$ /IL-2 production showed both CD8<sup>+</sup> and CD4<sup>+</sup> T-cell responses. All vaccinees had HIV-specific lymphoproliferative responses. All vaccinees reacted in diagnostic HIV serological tests and 26/29 (90%) had antibodies against gp160 after the second HIV-MVA boost. A high neutralizing antibody response rate (31-83% depending on the clade B or AE virus tested) was demonstrated using a PBMC assay. In conclusion, this vaccine approach was safe and highly immunogenic.

## LIST OF PUBLICATIONS

- I. **Aboud S**, Urassa W, Lyamuya E, Mhalu F, Biberfeld G. Evaluation of HIV antibody and antigen/antibody combination ELISAs for use in an alternative confirmatory HIV testing strategy in Dar es Salaam, Tanzania. *J Virol Methods* 2006 August; 135(2):192 – 196.
- II. Lyamuya EF, **Aboud S**, Urassa WK, Sufi J, Mbwana J, Ndugulile F, Massambu C. Evaluation of simple rapid HIV assays and development of national rapid HIV test algorithms in Dar es Salaam, Tanzania. *BMC Infect Dis* 2009 February; 9(1):19.
- III. Nilsson C, **Aboud S**, Karlen K, Hejdeman B, Urassa W, Biberfeld G. Optimal blood mononuclear cell isolation procedures for gamma interferon enzyme-linked immunospot testing of healthy Swedish and Tanzanian subjects. *Clin Vaccine Immunol* 2008 April; 15(4): 585-589.
- IV. **Aboud S**, Nilsson C, Karlen K, Marovich M, Wahren B, Sandstrom E, Gaines H, Biberfeld G, Godoy-Ramirez K. Strong HIV-specific CD4<sup>+</sup> and CD8<sup>+</sup> T lymphocyte proliferative responses in healthy individuals immunized with an HIV-1 DNA vaccine and boosted with HIV-1 recombinant modified vaccinia virus Ankara (MVA) expressing HIV-1 genes. *Clin Vaccine Immunol* 2010 July; 17(7):1124-1131.
- V. Bakari M, **Aboud S**, Nilsson C, Francis J, Buma D, Moshiro C, Aris EA, Lyamuya EF, Janabi M, Earl P, Robb M, Marovich M, Wahren B, Pallangyo K, Biberfeld G, Mhalu F, Sandström E, for the HIVIS study group. Broad and potent immune responses to a low dose of intradermal HIV-1 DNA boosted with HIV-1 recombinant MVA among healthy adults in Tanzania. *Vaccine*, in press.

## LIST OF ABBREVIATIONS

Ab	Antibody
ADCC	Antibody-dependent cell-mediated cytotoxicity
ADC	Antibody-dependent cytotoxicity
ADCVI	Antibody-dependent cellular viral inhibition
Ad5	Adenovirus 5
Ag	Antigen
AIDS	Acquired Immune Deficiency Syndrome
APOBEC	Apolipoprotein B mRNA-editing enzyme, catalytic polypeptide-like
ART	Antiretroviral therapy
ARV	Antiretroviral
AT-2	Aldrithiol-2
AZT	Azidothymidine
CAF	Cell antiviral factor
CCR5	Chemokine receptor 5
CRF	Circulating recombinant form
CD	Cluster of differentiation
CDC	Centers for Disease Control and Prevention
cDNA	Complementary negative strand DNA
CEF	Cytomegalovirus, Epstein-Barr and influenza virus
CFSE	Carboxyfluorescein diacetate succinimidyl ester
CMV	Cytomegalovirus
CPT	Cell preparation tube
CTC	Care and treatment center
CTL	Cytotoxic T-lymphocytes
CXCR4	Chemokine receptor 4
DBS	Dried blood spot
DC	Dendritic cells
DNA	Deoxyribonucleic acid
EBV	Epstein-Barr virus
EC	Elite controllers
ELISA	Enzyme-linked immunosorbent assay

ELISpot	Enzyme-linked immunospot
Env	Envelope
FASCIA	Flourescent activated cell sorting for cell-mediated assay
FC-LPA	Flow-cytometry lymphoproliferation assay
FDA	US Food and Drugs Authority
Gag	Group-specific antigen
GM-CSF	Granulocyte macrophage-colony stimulating factor
Gp	Glycoprotein
HAART	Highly active antiretroviral therapy
HESN	Highly exposed seronegative
HIV	Human immunodeficiency virus
HIVIS	HIV vaccine immunogenicity study
HLA	Human leukocyte antigen
HVTN	HIV vaccine trials network
IAVI	International AIDS vaccine initiative
IFNs	Interferons
IFN- $\gamma$	Interferon-gamma
ICS	Intracellular cytokine staining
id	Intradermal
IL	Interleukin
im	Intramuscular
IMC	Infectious molecular clone
LIA	Line immune assay
LPA	Lymphoproliferation assay
LPS	lipopolysaccharide
LTNP	Long-term non-progressors
LTRs	Long terminal repeats
Mabs	Monoclonal antibodies
MBL	Mannose-binding lectin
MHC	Major histocompatibility complex
MIP	Macrophage inflammatory proteins
MPER	Membrane proximal external region
MSM	Men who have sex with men
MTCT	Mother to child transmission

MVA	Modified Vaccinia Virus Ankara
MUHAS	Muhimbili University of Health and Allied Sciences
NAAT	Nucleic acid amplification tests
Nabs	Neutralizing antibodies
Nef	Negative regulatory factor
NIH	National Institutes of Health
NIMR	National Institute for Medical Research
NK	Natural killer
NNRTI	Non-nucleoside reverse transcriptase inhibitors
NRTI	Nucleoside reverse transcriptase inhibitors
PBMC	Peripheral blood mononuclear cells
PBS	Phosphate buffered saline
PCR	Polymerase chain reaction
PEP	Post-exposure prophylaxis
PFU	Plaque forming unit
PHA	Phytohaemagglutinin
PMTCT	Prevention of mother to child transmission
PPD	Purified protein derivative
PrEP	Pre-exposure prophylaxis
PRR	Pattern recognition receptors
RANTES	Regulated upon activation, normal T-cell expressed and secreted
Rev	Regulator of virion
RNA	Ribonucleic acid
RT	Reverse transcriptase
SEAB	Staphylococcal enterotoxin A and B
SHIV	Simian/human immunodeficiency virus
SIV	Simian immunodeficiency virus
SMI	Swedish Institute for Communicable Disease Control
STIs	Sexually transmitted infections
Tat	Transactivating factor
TB	Tuberculosis
TFDA	Tanzania Food and Drugs Authority
Th	T-helper
TLR	Toll-like receptor

TNF- $\alpha$	Tumor necrosis factor-alpha
TRIM5- $\alpha$	Tripartite motif 5-alpha
tRNA	Transfer RNA
WHO	World Health Organization
UNAIDS	Joint United Nations Program on HIV and AIDS
VCT	Voluntary counseling and testing
Vif	Viral inhibition factor
Vpr	Viral protein R
Vpu	Viral protein U
Vpx	Viral protein X
VRC	Virus Research Center
WB	Western blot
WRAIR	Walter Reed Army Institute for Research



# CONTENTS

1	General Background.....	9
1.1	Introduction .....	9
1.2	The epidemiology of HIV infection.....	9
1.2.1	Global situation .....	9
1.2.2	HIV infection in sub-Saharan Africa.....	10
1.2.3	HIV and AIDS in Tanzania.....	11
1.3	Virology and replication cycle of HIV .....	12
1.4	HIV subtypes and genetic diversity .....	15
1.5	Modes of transmission of HIV infection .....	15
1.6	Immunopathogenesis of HIV infection .....	16
1.7	Natural history of HIV-1 infection .....	17
1.8	Innate immunity.....	19
1.9	Adaptive immunity.....	20
1.9.1	HIV-specific cellular immune responses.....	21
1.9.2	HIV-specific antibody response.....	22
1.10	Laboratory diagnosis of HIV infection.....	23
1.10.1	Detection of HIV antibodies .....	23
1.10.2	Detection of HIV antigens .....	25
1.10.3	Detection of viral nucleic acid .....	25
1.10.4	Virus isolation .....	26
1.11	Treatment of HIV-infected individuals .....	27
1.12	Prevention of HIV infection.....	28
1.13	Prevention of HIV infection by immunization.....	30
1.13.1	Challenges associated with development of an HIV-1 vaccine .....	30
1.13.2	Possible correlates of protection against HIV infection.....	31
1.13.3	Prophylactic HIV vaccine trials .....	31
2	Rationale of the study.....	37
3	Objectives .....	38
3.1	Broad objective.....	38
3.2	Specific objectives.....	38
4	Methods .....	39
4.1	Paper I and paper II .....	39
4.2	Paper III .....	44
4.3	Paper IV .....	44
4.4	Paper V .....	46
4.4.1	Quality of monitoring of PBMC purification technique and assays for the assessment of HIV-specific vaccine-induced immune responses in Tanzania .....	46
4.5	Ethical considerations.....	47

5	Results and discussion.....	48
	5.1 Evaluation of HIV antibody and antigen/antibody testing strategies for the diagnosis of HIV infection (Paper I and II)	48
	5.2 Processing of blood mononuclear cells for use in HIV vaccine trials (Paper III)	52
	5.3 Assessment of HIV vaccine-induced lymphoproliferative responses (Paper IV)	53
	5.4 Monitoring of immune responses in healthy individuals immunized with HIV-1 DNA and boosted with recombinant MVA (HIVIS03) (Paper V)	54
6	Conclusions .....	59
7	Acknowledgements .....	60
8	References .....	62

# **1 GENERAL BACKGROUND**

## **1.1 Introduction**

Acquired immunodeficiency syndrome (AIDS), which is characterized by a cellular immunodeficiency leading to life threatening opportunistic infections and/or Kaposi's sarcoma and malignant lymphoma was first described in the early 1980s [1-2]. AIDS is caused by two retroviruses, human immunodeficiency virus types 1 (HIV-1) and 2 (HIV-2) [3-6]. HIV-1 infection is found worldwide while HIV-2 infection has its epicenter in West Africa. HIV infection has spread extensively in most parts of the world but the highest prevalence and incidence of HIV infection are found in sub-Saharan Africa. HIV can be transmitted through sexual intercourse, blood and blood products including contamination during intravenous drug use and vertically from mother to child [7]. The primary target for HIV is the CD4<sup>+</sup> T-lymphocytes, which are crucial to the normal function of the human immune system. Laboratory diagnosis of HIV infection can be done by detection of HIV antibodies, HIV antigens and viral nucleic acids, and by virus isolation [8]. HIV infection can be treated by antiretroviral (ARV) drugs to prolong and improve the quality of life of HIV-infected individuals. There are several ways to prevent the spread of HIV infection including health education on HIV, condom use, HIV screening of blood and blood products, voluntary counseling and testing, diagnosis and treatment of sexually transmitted infections (STIs), pre (PrEP) and post exposure ARV prophylaxis (PEP), prevention of mother to child transmission (PMTCT) of HIV and male circumcision. A safe, successful and affordable vaccine would be the most effective means to prevent the spread of HIV infection especially in vulnerable and highly at risk populations throughout the world and in particular those living in sub-Saharan Africa where nearly 70% of people living with HIV are found.

## **1.2 The epidemiology of HIV infection**

### **1.2.1 Global situation**

WHO/UNAIDS estimated that at the end of 2009 globally there were 33.3 million people living with HIV including 30.8 million adults, 15.9 million women and 2.5 million children under 15 years [9]. The total number of people living with HIV in 2009 was more than 14% higher than the 28.6 million in 2001, and the prevalence in 15-49 year-adults was similar (0.8%). HIV prevalence in young women (15-24 yr.) was double (0.6%) compared to young men (0.3%). It is estimated that during the year

2009, 2.6 million people became infected with HIV which was 21% fewer than the 3.2 million at the epidemic's peak 12 years earlier in 1997. The incidence rate in adults was <0.1 in 2009. An estimated 1.8 million people died of AIDS-related illnesses worldwide which decreased from 2.1 million in 2004 [9] due to increased availability of antiretroviral therapy (ART), care and support to people living with HIV and AIDS and decreasing incidence. However, the number of orphans due to AIDS has increased from 10 million in 2001 to 16.6 million in 2009. At the end of 2009, 5.25 million people were reported to be receiving ART in low- and middle-income countries following revised guidelines on CD4<sup>+</sup> T-cell count for initiating treatment in adults and recommendations on ART for infants and children, adults and adolescents including pregnant women [10]. This represents an increase of over 1.2 million people from December 2008 [10]. Based on the new criterion for ART initiation (CD4<sup>+</sup> T-cell count  $\leq$ 350 cells/uL), ART coverage for eligible patients increased from 28% at the end of 2008 to 36% at the end of 2009 [10].

### **1.2.2 HIV infection in sub-Saharan Africa**

Sixty-seven percent of people living with HIV worldwide are found in sub-Saharan Africa and at the end of 2009, there were 22.5 million people living with HIV [9]. Approximately 54% of the people living with HIV infection (12.1 million) in the region were women in 2009 compared to 10.9 million women in 2001 [9]. The prevalence of HIV infection in 15-49 year-adults was 5% in 2009 compared to 5.9% in 2001. HIV prevalence in young women (15-24 yr.) was more than double (3.4%) compared to that in young men (1.4%). Sub-Saharan Africa remains the most heavily affected region globally accounting for 69% of all new HIV infections in 2009 with an estimated 1.8 million people. The HIV incidence has fallen by more than 25% between 2001 and 2009 in 33 countries in the world of which 22 are in sub-Saharan Africa. The HIV incidence rate in adults was <0.41 in 2009 compared to 0.61 in 2001 [9]. Seventy-two percent of the total global AIDS deaths occurred in the sub-Saharan region in 2009 with an estimated 1.3 million people. The estimated number of orphans due to AIDS in the region was 14.8 million [9]. Sub-Saharan Africa had the greatest increase in the number of people receiving ARV treatment in 2009, from 2,950,000 at the end of 2008 to 3,911,000 a year later [10]. Eight low- and middle-income countries including Botswana had already achieved universal access to ART at the end of 2009 [10]. At 39%, ART coverage in the region was higher among women compared with 31% among men. In 2009, the average retention rate at 12 months across low- and middle-

income countries was 82% and was approximately the same among men and women [10].

### **1.2.3 HIV and AIDS in Tanzania**

In Tanzania, cases of AIDS were first observed in the Kagera region at the end of 1983 [11]. Early sero-epidemiological studies showed that the prevalence and incidence of HIV-1 infection differed considerably in various parts of the country and in various population groups [11-24]. A population-based study conducted in the Kagera region in 1987 showed that the HIV-1 seroprevalence among adults was 24.2% in the Bukoba urban zone, 10% in the neighbouring Bukoba rural and Muleba area and only 0.6% in more remote rural areas [13]. A subsequent study in the Kagera region showed a fall in HIV seroprevalence among adults in Bukoba urban to 18.2% in 1993 and down to 13.3% in 1996 and the decline was most significant in young women [25]. Furthermore, the high incidence of 47.5 per 1000 person years in 1989 in the Bukoba urban area declined to 9.1 per 1000 person years in 1996 [25]. In the Kagera region, age-adjusted prevalence of HIV infection among antenatal clinic attendees decreased from 22.4% in 1990 and down to 13.7% in 1996 [26].

In Dar es Salaam, the prevalence of HIV infection among pregnant women increased from 1.3% in 1984-1985 [27] and 3.6% in 1986 [11] up to 15.2% in 1993 [19] and then declined to 13.7% in 1996 [23], 11% in 2001-2003 [28] and 11.1% in 2004-2006 [29]. A national surveillance of HIV infection conducted among antenatal clinic attendees in 2003-2004 showed that the Mbeya region had the highest prevalence of HIV infection (15.7%) followed by Dar es Salaam (10.8%) and Tanga (9.2%) regions while the Kagera region (4.7%) had the lowest HIV prevalence [30]. The prevalence among blood donors in Dar es Salaam rose from 2% in 1984-1985 to 10% in 1988 [27] and then declined to 8.7% in 1999 [31] and 3.8% in 2004-2005 [32]. The overall prevalence of HIV among voluntary blood donors also decreased from 4.0% in 2006 to 2.7% in 2008 [33].

UNAIDS estimates that at the end of 2009 there were around 1.4 million people living with HIV including 1.2 million adults and 730,000 women and 160,000 children under 15 years in a total population of 41 million [9]. The overall HIV prevalence in adults was 5.6% in 2009 compared to 7.1% in 2001. HIV prevalence in young women between 15 and 24 years was more than double (3.9%) compared to

1.7% in young men. An estimated 100,000 people (88,000 adults and 12,000 children) became newly infected in 2009 [9]. The incidence rate in adults was 0.45 in 2009 compared to 0.64 in 2001. An estimated 86,000 people died of AIDS-related illnesses in 2009 compared to 110,000 people in 2001. The number of orphans due to AIDS increased from 840,000 in 2001 to 1.3 million in 2006 [9].


In 2008, the Tanzanian Ministry of Health and Social Welfare reported that about 85% of HIV transmission occurred through heterosexual sex followed by mother to child transmission (MTCT) (6%) and less than 1% through blood transfusion [33]. During the same year, the overall prevalence of HIV infection among voluntary counseling and testing (VCT) attendees was 11.4%, ranging from 3% in Tanga to 24.6% in Iringa regions [33]. The number of patients on ART by the end of March 2009 was 235,092 representing 55.6% of the 422,632 estimated numbers of ART eligible and 51.4% of 457,314 patients enrolled into HIV care and treatment center (CTC) services.

### **1.3 Virology and replication cycle of HIV**

HIV belongs to the subfamily lentivirinae and family retroviridae. There is 50% homology in the genome between HIV-1 and HIV-2. HIV-1 was reported to have been transferred from chimpanzees to humans at least three times to form the HIV-1 M, N and O groups [34]. Similarly, the origin of HIV-2 has been related to a transfer from sooty mangabey into human beings on multiple occasions [35].

HIV is a spherical enveloped RNA virus with a diameter of 80 to 120 nm. The envelope is a lipid bilayer containing viral glycoprotein and is acquired by budding from the host cell membrane. The envelope spikes are the glycoprotein gp120 which interacts with the CD4<sup>+</sup> molecule on the surface of T-lymphocytes and gp41 which mediates fusion of the HIV with the cell membrane of the CD4<sup>+</sup> T-lymphocyte. The envelope surrounds a capsid that contains two identical copies of positive strand single stranded RNA genome inside the core part of the virus (Figure 1). The virion which resembles a truncated cone also contains the reverse transcriptase and integrase enzymes. The HIV genome consists of three major genes that encode polyproteins for enzymatic and structural proteins of the virus including *gag* for gag-specific antigen, capsid, matrix and nucleic acid-binding proteins; *pol* for polymerase, protease and

integrase; and *env* for envelope glycoproteins. The genome also includes six accessory genes. The genome is flanked at its 5' and 3' end by long terminal repeats (LTRs) [36].



**Figure 1.**

(Source <http://www.avert.org/media-gallery/image-115-the-structure-of-hiv>)

HIV targets cells expressing the CD4<sup>+</sup> receptor, including T-helper lymphocytes, monocytes/macrophages and dendritic cells. Replication of HIV starts with binding of the viral glycoprotein spikes, the trimer of gp120 and gp41 molecules to the primary receptor, the CD4<sup>+</sup> protein and subsequently to one of the main chemokine co-receptors (Figure 2) either CCR5 (R5 viruses) or CXCR4 (X4 viruses). R5 viruses (also known as macrophage-tropic) predominate during early infection while X4 viruses (also known as T-cell-tropic) are more frequent during the advanced stages of infection [37]. A small percentage of people are resistant to infection because they have mutations in the CCR5 receptor gene [38]. HIV can also bind to a cellular adhesion molecule, integrin  $\alpha 4\beta 7$ , present on gut-associated lymphoid tissue. The transmembrane gp41 mediates fusion of the viral and cellular membranes which leads to the release of the viral core into the host cell. Once the genome is released into the cytoplasm after uncoating, the early phase of replication begins. The reverse transcriptase transcribes viral RNA to DNA which is transported to the cell nucleus and is integrated into the host cell chromosomal DNA. HIV reverse transcriptase is very prone to errors due to lack of proof reading ability and cause point mutations during transcription to proviral DNA [39-42]. Integration requires cell growth but the complementary negative strand DNA (cDNA) of HIV can remain in the nucleus and cytoplasm in a non-integrated circular DNA form until the cell is activated. Once integrated, the late phase begins and proviral DNA is transcribed as a cellular gene by the host RNA polymerase. Transcription of the genome produces a full-length RNA

which is processed to produce several mRNAs that contain the *gag*, *gag-pol*, or *env* gene sequences. The proteins translated from the *gag*, *gag-pol* and *env* mRNAs are synthesized as polyproteins and are subsequently cleaved to functional proteins. The envelopment and release of mature HIV virions occur at the cell surface. The HIV envelope picks up cellular proteins including major histocompatibility complex (MHC) molecules upon budding. HIV replication is regulated by six accessory gene products which are important in the life cycle of HIV. The Tat protein is a transactivator of transcription of viral and cellular genes while Rev protein regulates and promotes transport of viral mRNA into the cytoplasm. The Nef protein reduces cell surface expression of CD4<sup>+</sup> and MHC class I molecules, alters T-cell signaling pathways, regulates the cytotoxicity of the HIV and is required to maintain high viral loads. The Vif protein helps in virion assembly and promotes viral infectivity by mediating degradation of the intracellular antiviral apolipoprotein B mRNA-editing enzyme catalytic polypeptide-like (APOBEC-3G) factor [43]. Viral protein u (Vpu) reduces cell surface CD4<sup>+</sup> expression and enhances the release of virion. Vpr is important for transport of cDNA into the nucleus and for arresting of cell growth [36].

## Replication Cycle of HIV




Figure 2.

(Source <http://www.avert.org/media-gallery/image-875-replication-cycle-of-hiv>)



#### **1.4 HIV subtypes and genetic diversity**

HIV-1 consists of 3 groups called M (major), O (outlier) and N (non M or O) [44]. Eight HIV-2 groups have been described so far [45]. Nine HIV-1 clades (or subtypes) have been described within the M group [46-47] and are designated A to D, F to H, J and K. There are also circulating recombinant forms (CRFs). Globally, clades A through D and the CRF-01AE and CRF-01AG recombinants account for more than 90% of infections worldwide [48]. Close to 75% of the new infections occurring in the world are caused by subtypes A, C, and CRF-02AG. Clade C is the most prevalent in the world spreading through Central Africa down to South Africa. Clade C is also becoming dominant in parts of China, India and Ethiopia and may present up to 50% of all HIV infections worldwide. In the group M, clade A is found primarily in Central Africa, clade B in North Africa, North and South America and Europe, clade C in South Africa and India, and clade D in Central Africa. Subtype F has been isolated from Brazil [49]. In Tanzania, the prevalent HIV-1 subtypes are A, C, D and CRFs [50-54] and no HIV-2 infections have been reported to date. Other subtypes of group M include viruses from Russia (G) [55], Africa in Zaire (clade J) [56] and Cameroon (clade K) [57]. There are 16 recognized CRFs derived from the group M HIV isolates [46-47]. Subtype E (A and E) which is prevalent in Thailand has been renamed CRF-01AE [58]. CRF-02AG dominates the HIV epidemic in some parts of Africa [59]. In addition to the M group, other isolates initially found in Cameroon [60] are considered outliers and form the O group which has also been found at low frequency in other African countries [60]. The N group of HIV-1 has been found in a few HIV-infected individuals in Cameroon [46, 61]. The enormous HIV genetic diversity may have implications for possible differential rates of HIV disease progression, response to ART, emergence of resistance to ARV drugs and development of vaccine [62].

#### **1.5 Modes of transmission of HIV infection**

AIDS was initially described in homosexual and bisexual men and intravenous drug abusers [2, 63-67]. HIV can be transmitted through sexual intercourse, exposure to infected blood and blood products, intravenous drug use [7, 68-69] and vertically from mother to child [70-74]. HIV can also be transmitted through use of infected needles and surgical instruments and accidental needle-stick injury [75]. HIV is primarily transmitted through heterosexual intercourse in sub-Saharan Africa including Tanzania [76]. High viral load [77], high-risk sexual behavior including having multiple sex partners and the presence of STIs increase the risk for HIV transmission [21, 78-79].

The number of infectious viruses and infected cells are highest during acute and symptomatic infection, especially AIDS [80-85]. Presence of cell free infectious virus and/or virus infected cells has been demonstrated in the seminal and vaginal fluids in 10 to 30% of specimens tested from HIV-infected individuals [83, 86-92]. It has been reported that clade C virus infection was associated with increased HIV-1 vaginal shedding [93]. Another study showed that subtype C was preferentially transmitted in utero compared to subtype A and D [94]. MTCT of HIV is associated with high viral loads in blood and breast milk, a larger number of infected breast milk cells and mastitis in HIV-infected breastfeeding mothers [95-96].

### **1.6 Immunopathogenesis of HIV infection**

CD4<sup>+</sup> T-lymphocyte depletion and chronic immune activation are central immunopathogenic features of HIV infection. Possible mechanisms of CD4<sup>+</sup> T-cell destruction include a direct cytopathic effect of HIV and its proteins, apoptosis induced by immune activation, CD8<sup>+</sup> T-cell cytotoxicity and ADCC activity [37]. The decrease of CD4<sup>+</sup> T-cell counts and the level of HIV-1 viral load in plasma correlate with disease progression [97]. Immune activation changes include polyclonal B cell activation, increased CD8 and CD4<sup>+</sup> T-cell expression of activation markers such as CD38 and HLA-DR, increased T-cell turnover and elevated serum levels of proinflammatory cytokines and chemokines [98]. Immune activation measured as elevated expression of CD38 on CD8<sup>+</sup> and CD4<sup>+</sup> T-cells has been reported to be a better predictor of disease progression than plasma viral load [99]. A recent study of chronically HIV-1-infected individuals in Uganda showed that levels of CD4<sup>+</sup> T-cell activation measured as expression of CD38, HL-DR and the programmed death (PD-1) receptor correlated directly to viral load and inversely to CD4<sup>+</sup> T-cell count and that the levels of these cells also correlated to plasma levels of soluble CD14 and IL-6 which are markers of innate immune activation [100]. High-level chronic immune activation is found in pathogenic simian immunodeficiency virus (SIV) infection in macaques but not in non-pathogenic SIV infection in natural non-human primate hosts [98].

Following sexual transmission, CD4<sup>+</sup> T-cells and Langerhans cells are the first targets of HIV [101-102]. There is evidence that a single CCR5 virus usually is responsible for initial sexual infection. Studies of early infection in the SIV macaque model have shown that following vaginal SIV inoculation, central memory CD4<sup>+</sup> T-cells expressing high levels of the  $\alpha 4\beta 7$  integrin receptors are the predominant early target cells [103].

These cells were also shown to include Th17 cells which are important in the defence against bacterial infections. These cells are abundant in the gut-associated lymphoid tissue. After initial propagation of virus in the mucosa for a few days at the mucosal portal of entry, infection is spread to draining lymph nodes. Dendritic cells (DC) can bind virus particles and contribute to the spread of virus to the lymph nodes where activated CD4<sup>+</sup> T-cells are targets for further infection. Subsequent dissemination of infection to gut-associated and other lymphatic tissues results in a massive depletion of memory CD4<sup>+</sup> T-cells, especially in the gastrointestinal tract [101-102]. Damage to the mucosal barrier in the gastrointestinal tract results in translocation of microbial products, e.g. lipopolysaccharide (LPS), into the systemic circulation [98]. Studies in chronically HIV-infected individuals and in SIV-infected macaques have shown that circulating microbial products are a cause of systemic immune activation [104].

During the acute HIV infection the viral replication is very high. Viral RNA is usually first detectable in plasma one to two weeks after initial infection. After the initial peak the plasma viral RNA declines and reaches a viral set point two to six months after the initial infection. The initial decline of viremia coincides in time with the appearance of HIV-specific CD8<sup>+</sup> T-cells [105-106]. The viral load increases during the advanced stages of HIV disease (Figure 3). The rapid decrease of CD4<sup>+</sup> T-cells during the acute HIV infection is followed by an increase of the CD4<sup>+</sup> T-cell count after the resolution of the primary infection. However, subsequently there is a gradual decline of CD4<sup>+</sup> T-cells during the course of infection (Figure 3). An impairment of HIV-specific CD4<sup>+</sup> T-cell function occurs early in infection which is then followed by defects in CD4<sup>+</sup> T-cell responses to other recall antigens and to novel antigens [107].

### **1.7 Natural history of HIV-1 infection**

HIV disease progresses from acute primary infection to a chronic asymptomatic phase followed by a symptomatic phase leading to full-blown AIDS [108-109]. Studies on the natural history of HIV-1 infection conducted in resource-rich countries have shown that in ART-naive HIV-infected individuals the time from seroconversion to development of AIDS is about 10 years [110-112]. The natural history of HIV infection has also been documented from studies conducted in Africa [113-119]. Studies in Uganda and Tanzania [116, 119] showed that the rates of HIV-1-associated disease progression and CD4<sup>+</sup> T-lymphocyte decline were similar to those reported in Europe and the US. In contrast, in a study of female sex workers in Kenya a rapid clinical progression from

HIV-1 seroconversion to AIDS was reported [113]. HIV-2 infection is characterized by lower viral load and slower progression to AIDS than HIV-1 infection [120].

The initial symptoms following acute phase of HIV infection may resemble those of influenza or infectious mononucleosis. As in mononucleosis, the symptoms arise from immune response triggered by a widespread infection of lymphoid tissue. These symptoms subside spontaneously after 2 to 3 weeks and are followed by a period of asymptomatic infection or a persistent generalized lymphadenopathy that may last for several years. During this clinical latency period, the virus continues to replicate mainly in the lymphoid tissue. In intermediate immunodeficiency, HIV replication is very high and CD4<sup>+</sup> T-cell turnover is rapid. Deterioration of the immune response is indicated by increased susceptibility to opportunistic pathogens.

Full-blown AIDS usually occurs when the CD4<sup>+</sup> T-cell counts are less than 200/ $\mu$ L and involves the onset of more significant diseases including HIV wasting syndrome and occurrence of indicator diseases such as malignancy or opportunistic infections. Opportunistic pulmonary infections including tuberculosis (TB) and *Pneumocystis jirovecii* pneumonia are the major causes of morbidity and mortality in AIDS patients [121]. Oral candidiasis, cerebral toxoplasmosis, cryptococcal meningitis, pneumococcal infections, bacterial enteritis and prolonged and severe viral infections caused by cytomegalovirus (CMV), herpes simplex virus types 1 and 2 and varicella-zoster virus also occur [122]. The most notable malignancy to develop in patients with AIDS is the human herpesvirus 8-associated Kaposi's sarcoma, a rare and otherwise benign skin cancer that disseminates to involve visceral organs in immunodeficient patients [123]. Non-Hodgkin lymphoma and Epstein-Barr virus (EBV)-related lymphomas are also prevalent [124]. AIDS-related dementia may result from opportunistic infection or HIV infection of the macrophages and microglial cells of the brain. Studies in Africa showed that infection with HIV-1 subtype D is associated with faster disease progression compared to infection with other subtypes [125-128].




Figure 3. HIV-1 disease progression (Source <http://en.wikipedia.org/wiki/Hiv>)

### 1.8 Innate immunity

Innate immunity is the first line defense mechanism against HIV infection that can respond in minutes to a few days. It is characterized by its presence since birth, non-utilization of MHC molecules, non-specificity, lack of memory and its intensity does not increase with intensity of HIV exposure. Intact skin and mucosa serve as physical barriers to the HIV entry in the body. Chemical barriers such as low pH acts to create unfavorable environment for invading pathogens. Secretions in the mucosa such as defensins and type I interferons (IFNs) can inactivate HIV and prevent the entry through mucosa. Mannose-binding lectin (MBL) is another soluble factor with anti-HIV activity [129]. The innate immune system is comprised of several cell types, including DC, macrophages, neutrophils, natural killer (NK) cells, NK T-cells and  $\gamma\delta$  T-cells. Cells of the innate immune system recognize pathogen-associated molecular patterns of various pathogens, e.g. viral RNA and bacterial LPS, via pattern recognition receptors (PRR), such as Toll-like receptors (TLR) [130]. Activation of cells of the innate immune system results in the production of various cytokines, such as type I

IFNs, and  $\beta$ -chemokines, such as Regulated upon Activation Normal T-cell Expressed and Secreted (RANTES), Macrophage inflammatory proteins (MIP)-1 $\alpha$  and MIP-1 $\beta$  which can inhibit HIV replication [129, 131]. The  $\beta$ -chemokines can prevent HIV infection by blocking the CCR5 co-receptors. IFN- $\alpha$  activates NK cells which can kill virus-infected cells and produce IFN- $\gamma$  and other cytokines which help cytotoxic function of CD8<sup>+</sup> T-cells [132]. Furthermore, IFN- $\alpha$  up regulates the expression of the intracellular antiviral factors APOBEC3G and TRIM5- $\alpha$  [131]. Complement proteins can control HIV infection through several mechanisms, including lysis of virions in association with antibodies [133-134], binding to virions and activation of the alternative pathway [135], binding to gp120 and activation of the classical complement pathway [136] and increased HIV binding via immune complexes [137-138]. CD8<sup>+</sup> T-cell non-cytotoxic antiviral activity mediated by a soluble factor (CAF) is another component of the immune system with anti-HIV activity [129]. The activation of the innate immune system also contributes to the induction of adaptive immune responses.

Studies of possible correlates of protection in various cohorts of HIV-1 highly exposed seronegative (HESN) individuals, including female sex workers, partners of HIV-infected individuals and intravenous drug users, have demonstrated an association not only with HIV-specific cellular immune responses and mucosal HIV antibody responses but also with innate immune responses [139]. Increased NK cell activity including cytolytic activity and production of cytokines, e.g. IFN- $\gamma$  has been associated with resistance to HIV in HESN individuals. Protective NK receptor alleles have also been shown to be more frequent in HESN individuals than in HIV-infected individuals. Furthermore, increased DC responses and production of antiviral soluble factors including  $\beta$ -chemokines and defensins have been associated with reduced risk of HIV infection in HESN individuals [139].

### **1.9 Adaptive immunity**

Adaptive immunity is characterized by its acquisition after exposure to HIV, specificity, keeping of memory, antigen recognition by either MHC class I or II, and by the increasing intensity of immunity with increasing intensity of exposure. Adaptive immunity consists of cell and antibody mediated immune responses.

### 1.9.1 HIV-specific cellular immune responses

CD4<sup>+</sup> and CD8<sup>+</sup> T-lymphocytes play major roles to fight HIV infection. CD4<sup>+</sup> T-lymphocytes, also called T-helper (Th) cells, recognize antigens in association with MHC class II. CD4<sup>+</sup> T-lymphocytes secrete cytokines which activate other cells of the immune system. CD4<sup>+</sup> T-cells can also have cytolytic antiviral activity [140]. There are several subsets of CD4<sup>+</sup> T-lymphocytes including Th1, Th2, Th17 and regulatory T-cells. Th1 cells produce IFN- $\gamma$  and tumor necrosis factor (TNF) which have a significant role in the control of HIV infection. Th1 cells also produce IL-2 which causes activation and differentiation of CD8<sup>+</sup> T-cells. Th2 cells produce IL-4, IL-5, IL-6 and IL-13 which facilitate priming of humoral immune response and clearance of extracellular pathogens. HIV-specific CD4<sup>+</sup> T-cell proliferative responses resulting in the production of IFN- $\gamma$  and  $\beta$ -chemokines have been shown to be associated with control of HIV replication and prevention of HIV disease progression [141].

CD8<sup>+</sup> T-lymphocytes, also called cytotoxic T-lymphocytes (CTL), recognize HIV-infected cells in association with MHC class I. Activated CD8<sup>+</sup> T-cells release perforin and granzymes A and B which target HIV-infected cells and induce apoptosis [142-144]. CD8<sup>+</sup> T-cells can also induce apoptosis of target cells by ligation of Fas. Furthermore activated CD8<sup>+</sup> T-cells produce antiviral cytokines such as IFN- $\gamma$  and TNF- $\alpha$ . HIV-specific CD8<sup>+</sup> CTL activity has been shown to be associated with the initial control of viremia in acute HIV-1 infection [105-106]. HIV-specific CTL activity declines with disease progression [145]. In the macaque SIV infection model, depletion of CD8<sup>+</sup> T-cells led to a marked increase of viremia [146-147]. Data from a large cohort study among 578 treatment naïve HIV-infected individuals from KwaZulu-Natal in South Africa and a smaller study in Tanzania among 56 female bar workers showed that CD8<sup>+</sup> T-cell responses to Gag were associated with low viral loads [148-149]. Furthermore, HIV-infected female bar workers with HLA class I alleles B5801, B8101 and B0702 had lower viral loads compared to other alleles [149]. Certain HLA types including HLA-B27 and HLA-B57 have been reported to be associated with slow HIV disease progression [37].

HIV-1 specific CD4<sup>+</sup> and CD8<sup>+</sup> T-cell responses have been observed in HIV-exposed uninfected individuals [150-151]. Recently, HIV-specific lymphoproliferative responses have been associated with reduced acquisition of HIV in commercial sex

workers in Kenya [152]. Long-term non-progressors (LTNP) have been reported to show a stable CD4<sup>+</sup> T-cell count and variable but low viral load [153]. Elite controllers (EC) demonstrate a stable CD4<sup>+</sup> T-cell count and viral load of <50 copies/mL of plasma [154]. LTNP and EC show a higher HIV-specific CTL activity with increased levels of functional granzyme B and perforin compared to that seen in progressors [155]. Furthermore, LTNP show broader and more polyfunctional HIV-specific immune responses compared to progressors [156]. High CAF activity has also been demonstrated in LTNP [37].

### **1.9.2 HIV-specific antibody responses**

HIV antibodies are usually detectable 3 to 4 weeks after HIV infection [8]. HIV antibodies circulate in the blood and are also found in mucosal surfaces. HIV-1 specific binding antibodies are detected earlier after initial infection than neutralizing antibodies (Nabs). Nabs are directed against HIV gp120 and gp41 [48, 157-158]. The Nabs develop too late to influence the course of the acute HIV infection. The earliest Nab response is usually specific for the early autologous virus. However, viral mutants develop which are resistant to the Nabs and the Nabs in chronically infected subjects can usually neutralize early virus isolates but not concurrent autologous virus variants. It has been reported that approximately 20% of chronically HIV-infected individuals develop Nabs that can neutralize several heterologous primary virus isolates but only 2% have high titers of broadly cross-reacting Nabs against most HIV-1 strains [159]. Rare broadly neutralizing monoclonal antibodies (Mabs) directed against different epitopes of gp120 or against the membrane proximal external region (MPER) of gp41 have been identified [159-160]. Recently two new broadly neutralizing Mabs called PG9 and PG16 with reactivity to conserved regions of variable loops of gp120 have been generated from a clade A-infected African donor [161]. Passive immunization experiments in macaques using broadly neutralizing Mabs or polyclonal IgG showed that these antibodies could protect against simian/human immunodeficiency virus (SHIV) infection [160]. Nabs to HIV-1 have been demonstrated in the cervical fluid in HIV HESN [151]. Furthermore, genital neutralizing IgA has been reported to be associated with reduced acquisition of HIV infection in Kenyan female sex workers [152].

Antibodies to HIV Env have also been shown to mediate antibody-dependent cellular cytotoxicity (ADCC) and antibody-dependent cell-mediated virus inhibition (ADCVI)



through binding to Fc receptors on effector cells, such as NK cells and monocytes [162-166]. A study of the Multicenter AIDS Cohort in the US showed that rapid progressors had significantly lower ADCC antibody titers as compared to nonrapid progressors [167]. A study of HIV-infected individuals with undetectable viral replication showed that these individuals had higher ADCC antibody titers than viremic individuals [168]. It has been reported that macaques vaccinated with replicating recombinant adenovirus 5 (Ad5)-SIV followed by SIV gp120 developed ADCC antibody activity which correlated with reduced acute viremia after intrarectal SIV challenge [169].

## **1.10 Laboratory diagnosis of HIV infection**

### **1.10.1 Detection of HIV antibodies**

HIV-specific antibody detection is the most commonly used approach for the diagnosis of HIV infection. However, antibodies usually appear about 3-4 weeks after initial HIV infection [8]. Several types of assays for HIV antibody detection have been developed and promoted for HIV screening and diagnosis [8]. Enzyme-linked immunosorbent assay (ELISA) is the most commonly used technique for screening purposes in developed countries, followed by confirmatory testing most commonly by using conventional Western blot (WB). There are many different commercially available ELISAs for detection of antibodies to HIV. In 1985, first-generation indirect ELISAs employed whole virus antigens obtained from cell cultures which were bound to the solid phase on the bottom of the wells of microtitre plate [170]. The first generation ELISAs were sensitive but less specific with capacity to detect early HIV antibodies slightly more than 40 days after infection [170]. The second-generation ELISAs used an indirect format, HIV recombinant antigens and peptides bound in solid phase [171]. The assays had increased specificity and good sensitivity that reduced the window period to detect antibodies as early as 33-35 days after infection [171]. In 1990s, due to diverse HIV variability, ELISAs were introduced which also included antigens from HIV-2 and new antigens from viruses of the HIV-1 groups M, N and O [UNAIDS [172-173]. Third generation ELISAs which used antigen sandwich technique and included recombinant HIV-1 and HIV-2 proteins and/or peptides bound on a solid phase either in the bottom of microplate or a bead were introduced in 1994 [171]. These ELISAs had higher sensitivity and specificity and reduced the window period to about 22 days after infection [171]. Fourth-generation ELISAs that can detect both HIV p24 antigens and antibodies have been introduced recently. These assays offer advantages of early detection of acute HIV infection by reducing the window period to almost the

levels of the detection of HIV RNA [171, 174]. Fourth generation ELISAs have been used in developed countries [175-177] and introduced in resource-limited settings in recent years.

There are several simple rapid HIV assays that are used for the diagnosis of HIV infection. The assay principles are based on particle agglutination, immunodot, immunofiltration and immunochromatography [178-183]. The assays offer several advantages including utilization of whole blood or capillary blood obtained from a finger prick, lack of requirements for laboratory facility, affordability, expansion of access to HIV testing and giving results within 15-30 minutes on the same day. There are a number of simple rapid assays that do not require refrigeration [178-183]. Many rapid tests contain a built-in internal control such as a control band indicating whether the samples and reagents have been added correctly to ensure accuracy and reliability of results. Presently, many rapid tests include antigens from both HIV-1 and HIV-2. There are two commercially available fourth generation rapid HIV tests.

The most commonly used confirmatory antibody assays are WB and line immune assays (LIA). The WB consists of HIV denatured proteins, separated by electrophoresis according to size and blotted on strips of a nitrocellulose membrane which are then incubated with patient serum [8]. HIV-1 proteins detectable by WB include the Env (envelope) glycoproteins (gp41, gp120, gp160), the Gag (p17, p24/p25, p55) and the Pol (p34, p40, p52, p68). Most of the commercially available Western blots include also a protein from HIV-2 in order to detect both HIV-1 and HIV-2 infections. The consortium for retrovirus serology standardization recommends the presence of at least one of the gp120 or gp160 proteins and one of p24 or p32 proteins for a positive WB [184]. CDC considers a positive WB if at least two of the p24, gp41, and gp120/160 proteins are present [185-186]. WHO recommends a positive WB if only two Env bands are found [186]. WB is limited by the high costs, unavoidable subjectivity when reading and interpreting results and frequent occurrence of indeterminate results that can delay the diagnosis and increase costs. LIA such as Inno-Lia assay are based on recombinant proteins and/or synthetic peptides capable of detecting antibodies to specific HIV-1 and/or HIV-2 proteins. The assays produce fewer indeterminate results as compared to WB but are equally expensive.

Due to high costs, WB is not used routinely as a confirmatory antibody assay in resource-limited countries but applied to resolve discrepancy between two ELISAs or in rapid HIV testing algorithms where ELISA could not resolve the discrepancy. Several studies in resource-limited countries have shown that a combination of antibody ELISAs based on different test principles and/or different antigens can be used in alternative confirmatory testing strategies [187-194]. Combinations of various simple rapid HIV assays have also been evaluated for use in alternative confirmatory HIV testing strategies and when carefully selected can perform similar to more conventional ELISA and WB combinations [192, 195-202]. Simple rapid assays are commonly used for the diagnosis of HIV infection in VCT, PMTCT and CTC facilities in resource-limited settings [197-199].

### **1.10.2 Detection of HIV antigens**

The p24 antigen can be detected by an ELISA in which the solid phase consists of antibodies to p24 antigen of HIV. The assay detects the viral protein p24 in the blood of HIV-infected individuals where it exists either as unbound or bound to anti-p24 antibodies. Several studies have been conducted to evaluate the performance of p24 antigen assay for the diagnosis and monitoring of HIV infection in infants [203-214]. The sensitivity of the assay has increased with modifications introduced to dissociate p24 antigen from anti-p24 antibodies [215]. Ultrasensitive p24 antigen assay performed on plasma samples for the diagnosis of HIV infection showed a sensitivity of 97% to 100% within the first 6 months of life [207, 209, 212, 216]. The assay has been used much less frequently than HIV-1 DNA or RNA amplifications tests because of the relative poor sensitivity of p24 antigen assay, absence of readily available FDA-approved reagents and high costs in resource limited settings. Recently, a study conducted in South Africa has reported on the development of a p24 antigen rapid test for the diagnosis of acute HIV infection in infants with an overall sensitivity of 95% and specificity of 99% [217].

### **1.10.3 Detection of viral nucleic acid**

Nucleic acid amplification tests (NAAT) can detect acute HIV infection by detecting HIV-1 RNA as early as 9 days before seroconversion [218]. Very sensitive methods for detecting plasma HIV RNA include target nucleic acid sequence-based amplification, reverse transcriptase-polymerase chain reaction (PCR) and signal branched-chain DNA amplification [219]. HIV-1 RNA PCR is commonly used to diagnose HIV-1 infection

in infants in high-income countries [219]. Detection of viral RNA to levels of ~50 copies/mL or lower can be achieved [220]. More recent viral RNA assays can even detect virus levels as low as 2 RNA molecules/mL [221-222]. The half-life of HIV is so short that it is estimated that half the entire plasma virus population is replaced in <30 minutes [223]. Use of HIV-1 RNA assays for the diagnosis of HIV-1 infection in infants has been reported in several studies [224-236] with reported sensitivity ranging from 25% to 50% within the first few days of life to 100% by 6 to 12 weeks of age [226, 228]. HIV-1 RNA assays are used commonly for monitoring response to ART and as a prognostic marker for HIV disease progression where affordable in resource-limited settings.

HIV-1 DNA PCR test using peripheral blood mononuclear cells (PBMC) has been used in low resource settings for early infant diagnosis of HIV infection in children less than 18 months [50, 237]. The use of venous blood sample has limitations including lack of expertise needed for venipuncture of small infants, transportation and storage at 2-25 °C, and processing within 4 days of specimen collection. Various studies in several settings have demonstrated excellent results using dried blood spot (DBS) specimen, which has the advantages of requiring only a few drops of blood (20-50 µL) obtained from a heel prick and applied to the filter paper. Once dried, a filter paper can be stored at room temperature eliminating the need to store and transport whole blood at 2-25 °C [238-241]. Use of filter papers also provides fewer chances for mislabelling though it can occur, because there are fewer transfer steps once the blood is applied to the paper. The DNA in the filter paper also remains stable for a longer time. Recently, usefulness of DBS specimens has been emphasized as a means for ensuring greater accessibility to HIV testing for the paediatric population [242]. DBS specimens have also been used for viral loads to detect HIV infection in resource-limited settings.

#### **1.10.4 Virus isolation**

The use of virus culture for the laboratory diagnosis of HIV-1 infections in infants and young children has been reported previously [203, 224, 243-246]. Virus isolation has remained as a research method, however, its use is limited by the fact that it is labor intensive, time consuming, costly, requires biosafety level 3 facility and well trained laboratory personnel, and poses a biohazard risk. The availability of viral culture facilities for routine use is limited in resource-constrained settings.

### **1.11 Treatment of HIV-infected individuals**

The primary goals of ART are suppression of viral load to undetectable level, restoration and/or preservation of immunologic function, improvement of quality of life, and reduction of AIDS-related morbidity and mortality. There are six groups of licensed antiretroviral drugs that are available for treatment including binding inhibitors, fusion-penetration inhibitors [Maraviroc, Enfuvirtide], nucleoside reverse transcriptase inhibitors (NRTI) [abacavir, emtricitabine (FTC), zidovudine (AZT), didanosine (ddI), zalcitabine (ddC), lamivudine (3TC), tenofovir (disoproxil fumarate), and stavudine (D4T)], non-nucleoside reverse transcriptase inhibitors (NNRTI) [nevirapine, efavirenz (EFV)], integrase or protease inhibitors [247-248]. AZT was the first successful antiretroviral drug which came to use in 1987.

ART is currently given as a cocktail of several ARV drugs called highly active antiretroviral therapy (HAART). The use of triple therapy with different mechanisms of action has less potential to lead to resistance to ARV drugs. Multidrug therapy can reduce plasma viral load to undetectable levels and the widespread use of HAART has dramatically reduced morbidity and mortality due to AIDS [249-250]. There are several different regimens but each regimen depends on several factors. In resource-rich countries first line HAART usually includes a protease inhibitor which is an expensive regimen. In many developing countries including Tanzania, two NRTI drugs and one NNRTI drug are given to HIV-infected individuals when initiated on ART [251]. Some HAART are combined in a single pill to enhance compliance to ART. The use of ARV drugs is associated with problems including poor adherence, development of side effects and emergence of HIV resistance to the ARV drugs. Significant side effects include for instance anemia and neutropenia due to bone marrow suppression by AZT and liver toxicity by nevirapine. Customization of the HAART for each patient can minimize the ARV drug side effects, ease the pill-taking regimen and allow the patient to return to nearly normal health and lifestyle.

According to the current HIV care and treatment strategy in Tanzania, ART should be initiated for individuals showing symptoms of AIDS, AIDS-defining illness or if CD4 T-cells drop below 200 cells/ $\mu$ L [251]. However, WHO has recently revised the criterion for ART initiation to be CD4<sup>+</sup> T-cell count  $\leq$ 350 cells/ $\mu$ L [10]. In Tanzania, the first pilot HIV CTC in Dar es Salaam with availability of ART was set up in June 2004. The clinic was part of the National HIV care program that was started

countrywide to provide care and treatment including provision of free ARV drugs [252]. A recent study conducted in treatment-naïve HIV-infected individuals in Dar es Salaam showed resistant mutations that were associated with drugs currently used in first-line therapy and in the PMTCT of HIV which can result in treatment failure and the spread of ARV-resistant strains [54].

### **1.12 Prevention of HIV infection**

There are several ways that can be used to prevent and control the spread of HIV infection. The principal way HIV infection can be controlled is by educating the population about the modes of transmission and measures that may curtail spread of HIV including monogamous relationship, safe sex practice, the use of condoms to reduce the possibility of HIV exposure and voluntary counselling and testing. A successful anti-HIV education campaign in Uganda has been cited as more effective than ARV drugs for saving lives of people [253]. In 2007, the president of Tanzania, Jakaya Kikwete, led the national campaign on voluntary HIV counselling and testing (himself and his wife underwent the test in public) to motivate Tanzanians to know their HIV status and take appropriate control measures thereafter. The national campaign led to voluntary testing of more than 3 million individuals in six months in the whole country. When male condom is used properly, it is thought to reduce HIV transmission by as much as 70% [254]. A female condom is also available and is an effective barrier to HIV and other STIs though its use is limited by high costs and low acceptance rates [255].

The proof-of-concept, double-blinded, placebo-controlled trial conducted by the Centre for the AIDS Programme of Research in South Africa (CAPRISA) showed that a vaginal microbicide candidate consisting of 1% tenofovir gel reduced the HIV incidence by 39% in South African women [256]. Male circumcision has been reported to reduce transmission of HIV-1 by 50%-60% in Kisumu, Kenya and Rakai, Uganda [257-258]. Contaminated needles are a major source of HIV infection in intravenous drug abusers and people must be educated that needles must not be shared. The reuse of contaminated needles in clinics was the source of outbreaks of AIDS in the former Soviet bloc and other countries [259-260]. In some high-income countries, efforts have been launched to provide sterile equipment to intravenous drug abusers [261-263].

Potential blood and organ donors are screened for HIV and other blood born infections before they donate blood, tissue and blood products. People testing positive for HIV must not donate blood. People who anticipate a future need for blood such as those awaiting elective surgery, should consider donating blood beforehand. The Tanzanian government introduced nation-wide blood donation screening for HIV in 1989. Blood safety remains an issue of major concern in transfusion medicine in Tanzania where national blood transfusion services and policies, appropriate infrastructure, trained personnel and financial resources are yet to satisfy increased demands. National blood transfusion services were established in 2004 with aims to ensure availability of safe blood and blood products for transfusion to health facilities [33]. The strategy of blood donation is focused on low risk of HIV, voluntary non-enumerated blood donors and this has gradually discouraged replacement/family blood donors due to high-risk of transfusion transmissible infections [264].

Screening for STIs and providing early treatment prevent the transmission of HIV-AIDS [265]. In resource-limited settings, a syndromic approach has been adopted for the management of STIs [266-267]. PrEP has been shown to reduce the risk of HIV infection [268]. PEP which includes administration of ART within 72 hours after HIV exposure prevents the risk of infection [269]. Although AZT monotherapy may be effective in PEP, most PEP protocols specify dual or triple therapy because it is likely to be more effective than monotherapy [270].

Without interventions, the risk of MTCT of HIV varies from 14% to 48% and is highest in breastfeeding women [70]. The rate of MTCT of HIV has been reduced to less than 1% in resource-rich countries by the use of prophylactic HAART to the mother combined with caesarean section and avoidance of breastfeeding [271]. However, in many resource-limited countries the majority of HIV-infected women breastfeed since they do not have acceptable, affordable, sustainable and safe infant feeding options [272]. Short-course prophylactic ART around delivery which is used in many resource-limited settings significantly reduces MTCT of HIV but does not prevent postnatal HIV transmission through breastfeeding [273-274]. Several recent studies in sub-Saharan Africa [271, 275], including the Mitra [28] and Mitra Plus [29] studies in Tanzania have shown that prophylactic ART of HIV-infected mothers or their infants during breastfeeding prevents postnatal HIV transmission. Infant or maternal ARV prophylaxis for 6 months during breastfeeding in the Mitra and Mitra

Plus study, respectively, resulted in a similar low risk of acquisition of infection between 6 weeks and 6 months (1%) and a similar low cumulative infant HIV infection rate at 6 months of age (5%) [28-29].

### **1.13 Prevention of HIV infection by immunization**

HIV immunization is potentially the most effective and affordable strategy to reduce and to prevent the spread of HIV infection in the population worldwide. There are two main types of immunization, namely prophylactic and therapeutic. This thesis includes only studies of prophylactic immunization and therapeutic immunization will not be discussed. Several different types of HIV vaccines to prevent HIV infection have been evaluated in different phases of clinical trials [276-280].

#### **1.13.1 Challenges associated with development of an HIV-1 vaccine**

It is generally believed that an effective HIV vaccine should be able to elicit durable immunity including broadly Nabs systemically as well as mucosally and potent polyfunctional cellular immune responses, especially CTL responses [280]. However, there are several scientific challenges associated with the development of an HIV vaccine [281]. The greatest problem is the extremely high variability of HIV. The viral diversity is highest in sub-Saharan Africa, including Tanzania, where infections with different subtypes of HIV-1 are prevalent. Another major problem is that HIV infects cells of the immune system, mainly CD4<sup>+</sup> T-lymphocytes which have a central role in the induction of immune responses. Furthermore, HIV DNA integrates in the host cell genome and establishes a latent reservoir of infected cells. Infection may also be transmitted by infected cells. HIV has the ability to escape immune elimination through viral mutations. In addition, the envelope glycoprotein is heavily glycosylated which protects neutralization epitopes. Most successful vaccines against viral diseases are live attenuated or whole-killed virus vaccines. However, live attenuated vaccines are not being considered for use in humans because of the risk for reversion of an attenuated strain to a pathogenic strain. A way of mimicking the effect of live attenuated vaccines is to use live recombinant vectored vaccines. Infection of macaques with SIV or chimeric SIV-HIV are useful animal models for HIV vaccine studies but there is no appropriate animal model that allows the replication of HIV-1 and development of HIV disease similar to that seen in humans.



### **1.13.2 Possible correlates of protection against HIV infection**

The correlates of vaccine-induced protection against HIV infection in humans have not yet been identified. Only one HIV efficacy trial has shown modest vaccine-induced protection against infection [282]. Possible correlates of protection against HIV infection include broadly Nabs and other inhibitory antibodies such as ADCC antibodies, CD8<sup>+</sup> T-cell activity, especially cytotoxicity, CD4<sup>+</sup> T-cell activity and NK cell activity and other innate immune responses as described in the sections on cellular and humoral immune responses (1.9) and innate immune responses (1.8). Vaccine-induced antibodies should ideally be able to neutralize the incoming virus at the site of entry and prevent the spread to other parts of the body. However, it has so far proven difficult to induce broadly Nabs by immunization. If infection occurs after HIV exposure, vaccine-induced cellular immune responses will be needed to control virus replication and thereby prevent development of disease. Potential correlates of CD8<sup>+</sup> T-cell immunity against HIV including cytotoxicity, cytokine production, phenotypic markers and other markers, have been discussed recently in a review article [283]. A recent study of immune and genetic correlates of SIV vaccine-induced protection in a large number of macaques showed that a SIV-DNA prime/recombinant Ad5 boost vaccine regimen induced complete protection against mucosal infection with heterologous SIVsmE660 in 50% of the vaccinated monkeys. Protection was associated with low levels of Nabs and an envelope-specific CD4<sup>+</sup> T-cell response. Furthermore, monkeys that expressed two TRIM5 alleles were more often protected than those that expressed one TRIM5 allele. Vaccinated, SIV-infected monkeys which expressed the major histocompatibility class I allele Mamu-A\*01 had a lower peak plasma virus RNA level than control monkeys [284].

### **1.13.3 Prophylactic HIV vaccine trials**

In June 2011, more than 200 trials of HIV-1 vaccine candidates were listed in the International AIDS Vaccine Initiative (IAVI) clinical trials database [285]. More than 40 different HIV-1 vaccine candidates have been tested alone or in combination in clinical trials [280]. The most frequently tested HIV immunogens include Env subunits, DNA vaccines and live recombinant virus vaccines. Many HIV vaccine trials have been based on the heterologous prime boost approach which usually implies using HIV DNA plasmids or recombinant Env glycoprotein in combination with a nonreplicating viral vector based vaccine. The most commonly used viral vectors are poxvirus, including canarypox, MVA and NYVAC, and adenovirus [278, 286]. The earliest

vaccine trials focused on the use of Env proteins with the purpose of inducing neutralizing antibodies. The first phase I trial of a human candidate HIV vaccine was conducted in 1987 in the United States among 72 HIV-negative healthy adults using a recombinant envelope gp120 or gp160 given with alum adjuvant [287-288]. Studies in the chimpanzee HIV-1 infection model and the macaque SHIV infection model demonstrated that immunization with gp 120 could induce protection against challenge with the homologous virus strain but not against challenge with distant heterologous virus strains [280]. Several phase I clinical trials showed that rgp120 and rgp160 elicited antibodies which neutralized laboratory-adapted HIV-1 isolates but not primary HIV isolates [289]. Immunization with recombinant gp120 in two phase III efficacy trials failed to induce protection against HIV infection or delay HIV disease progression [290-292].

The first phase I vaccine trial in an African country started in 1999 in Uganda and included 40 HIV-seronegative volunteers who received a recombinant attenuated canary pox vaccine encoding Env, Gag and protease based on subtype B [293-294]. Subsequently more than 20 prophylactic vaccine trials have been conducted in Africa testing various HIV vaccines based on subtypes which are prevalent in that continent [277].

Canarypox vector based HIV vaccine constructs, called ALVAC, in combination with recombinant envelope glycoprotein vaccines have been evaluated in several phase I and phase II trials and in one phase III trial [277, 282, 295-296]. The first phase II trial with an ALVAC canarypox virus vector vCP205 expressing subtype B gp120, p55, and protease was conducted in the United States with 435 volunteers receiving or not receiving an HIV-1 SF-2 recombinant gp120 boost. The majority of volunteers (94%) given the canarypox vaccine plus gp120 had Nabs to the MN strain as compared to 56% of the volunteers given the canarypox vaccine alone. About one-third of the volunteers had anti-HIV cytotoxic T-lymphocytes whether they received gp120 or not [295]. Another phase I/II trial (RV135) with an ALVAC expressing CRF01\_AE HIV-1 gp120 linked to a portion of subtype B gp41 (vCP1521) and also expressing HIV-1 gag and protease was conducted in Thailand among 133 HIV-negative adults who also were boosted with a high or low dose of a bivalent HIV gp120 vaccine containing a B envelope from strain MN and a CRF01\_AE envelope from strain A244 (AIDSVAX B/E) [296]. Lymphoproliferative responses to gp120 E were shown in 63% of

vaccinees and HIV-specific CD8<sup>+</sup> CTLs in 24% of the vaccinees [296]. Nabs against HIV-1 subtype E were detected in 71% of the vaccinees. Furthermore, ADCC activity was demonstrated in 84% of vaccinees to CRF01-AE gp120 [297]. The vaccine combination used in the RV 135 trial was subsequently used in the RV144 phase III efficacy trial in Thailand [282].

HIV vaccines based on plasmid DNA and/or live recombinant virus vectors mainly stimulate cellular immune responses. T-cell vaccines are usually not expected to prevent acquisition of infection but to protect against development of disease by reducing the viral load. Several studies in the SIV and SHIV macaque models have shown that vaccines which predominantly elicit T-cell responses can control virus replication and delay or prevent CD4<sup>+</sup> T-cell decrease [298-300]. In a recent vaccine study in macaques using recombinant replication competent rhesus CMV expressing SIV Gag, Rev, Nef, Tat and Env, effector memory T-cell responses were elicited in the absence of Nabs and 4 of 12 vaccinated animals controlled rectal mucosal SIV infection without progressive systemic dissemination [301].

HIV DNA vaccines are usually poor immunogens when used alone in humans but they can efficiently prime immune responses when used in prime boost regimens with a live recombinant HIV vaccine [278]. The immunogenicity of HIV DNA vaccines can be enhanced by improving the delivery of the vaccine and by the use of adjuvants, such as IL-12, IL-15 and granulocyte macrophage colony-stimulating factor (GM-CSF) [302]. Use of needle-free injection devices, such as the Biojector, to deliver DNA vaccine has been shown to improve immunogenicity [303-304]. Electroporation has been shown to enhance DNA uptake and to increase the breadth of immune responses after administration of a multigene vaccine in rhesus macaques [305].

Phase I and II HIV vaccine trials of HIV-1 DNA and MVA encoding HIV-1 clade A p24/p17 sequences and a string of CD8<sup>+</sup> T-cell epitopes have been conducted in the UK and East Africa. The frequency of IFN- $\gamma$  enzyme-linked immunospot (ELISpot) responses was found to be less than 15% to Gag [276]. However, in a subsequent small trial that administered higher doses of these vaccine constructs, HIV-specific IFN- $\gamma$  ELISpot responses were demonstrated in 50% of the vaccinees [306]. The HIVIS01/02 phase I trial in Sweden evaluated priming with DNA expressing *gp160* of HIV-1 subtypes A, B and C; rev B; *p17/p24 gag* A and B, and *RTmut* B, given with the

Biojector on days 0, 30 and 90 and boosting 6 months after the last HIV-DNA immunization with heterologous MVA-CMDR expressing *env*, *gag* and *pol* of CRF01A\_E. The HIV-specific IFN- $\gamma$  ELISpot response rate was 92% (34/37), 86% to Gag and 65% to Env. A low dose of HIV-1 DNA administered id was as effective as a higher dose im in priming for the MVA boosting vaccination. The use of recombinant GM-CSF as an HIV-DNA adjuvant did not enhance the immune responses [304].

A recent DNA prime MVA boost phase I HIV vaccine trial was conducted among healthy individuals in the United States (HVTN 065) who were randomized to receive either placebo, 2 doses of DNA followed by 2 doses of rMVA (DDMM), or one dose of DNA followed by 2 doses of rMVA (DMM) or 3 doses of rMVA (MMM) [307]. The DNA and rMVA vaccines encoded Gag, Protease, RT and the native membrane-bound trimeric form of Env that produced noninfectious virus-like particles. Immune responses for CD4<sup>+</sup> (77% vs. 43%) and CD8<sup>+</sup> (42% vs. 17%) T-cells assessed by intracellular cytokine staining (ICS) were found to be highest in the DDMM group compared to the lowest in the MMM group [307]. Furthermore, the response rates for Env binding and Nabs were observed to be the highest in the MMM group [307].

A phase I trial which compared HIV DNA-C prime NYVAC-C boost to NYVAC-C vaccination alone was conducted among volunteers in Lausanne, Switzerland and London, UK (EV02). Volunteers were randomized to receive two doses of recombinant DNA and poxvirus vector NYVAC (DNA-C group; n=20) or two doses of NYVAC-C alone (NYVAC-C group; n=20). Both vaccines expressed HIV-1 clade C *env*, *gag*, *pol* and *nef* genes. HIV-specific IFN- $\gamma$  ELISpot responses were demonstrated in 90% (18/20) of vaccinees who received DNA-C and NYVAC-C compared to 33% (5/15) of vaccinees who received NYVAC-C alone [308-309]. The vaccine-induced T-cell responses were most frequently directed against Env [308-309]. Testing by ICS showed that both CD4<sup>+</sup> and CD8<sup>+</sup> T-cell responses were polyfunctional. However, CD4<sup>+</sup> T-cell responses were more frequent. T-cell responses were still demonstrable in 70% of vaccinees one year after the last immunization. Binding antibodies to Env gp140 were demonstrated in 75% of vaccinees who received DNA-C plus NYVAC-C. Tests for Nabs were negative [308-309].

A phase I/II HIV DNA prime rAd5 boost vaccine trial was conducted between May and October 2006 among 324 individuals (RV 172) from 3 East African countries

(Kenya, Tanzania and Uganda). The volunteers were randomized to receive placebo, a single dose of rAd5 at  $10^{10}$  or  $10^{11}$  particle units, or priming with 3 injections of multiclade HIV-1 DNA at 0, 1 and 2 months followed by the boost of a single dose of rAd5 at  $10^{10}$  or  $10^{11}$  particle units at 6 months [310]. The DNA vaccine consisted of HIV-1 *env* subtypes A, B and C and subtype B *gag*, *pol* and *nef* genes while the rAd5 expressed identical genes with the exception of *nef*. This was the first phase HIV vaccine trial to be conducted in Tanzania. The vaccine regimen was reported to be safe and well tolerated. HIV-specific T-cell responses assessed by IFN- $\gamma$  ELISpot were detected in 63% of vaccinees. Pre-existing Ad5 Nab titers influenced significantly the response rates in individuals who received rAd5 alone [310].

Four HIV vaccine efficacy trials have been conducted and one is ongoing [277]. The first two phase III efficacy trials used bivalent subtype B and subtype B/E envelope glycoprotein. One trial was conducted during 1998 and 1999 in the USA, Canada and the Netherlands among 5403 HIV-seronegative men who have sex with men (MSM) (VAX004) and the other trial included 2527 HIV-uninfected injection drug users in Bangkok, Thailand (VAX003). These trials did not show protection against HIV infection [290-292].

A test-of-concept trial in the United States (STEP), including about 3000 individuals, evaluated a recombinant adenovirus 5 (MRKAd5) vector vaccine expressing clade B Gag, Pol and Nef in a three-dose regimen [311-312]. In 2007, the trial was discontinued because the vaccine did not protect vaccinees from HIV infection and there was increased risk of HIV acquisition in vaccinated men who had pre-existing Ad5 antibody titres and were uncircumcised [311, 313]. A similar trial that was conducted in South Africa (Phambili) including heterosexual women and men was also stopped [314]. Another phase IIb trial (HVTN 505) is being conducted through VRC at the NIH in which a DNA vaccine consisting of clade B Gag, Pol, Nef, and Env plus clade A and C Env DNA is given as a prime followed by a boost with rAd5 vector that expresses a clade B Gag/Pol fusion protein and the clade A, B and C envelope glycoproteins to Ad5 antibody negative circumcised MSM [315].

The hope for getting an efficacious HIV vaccine was revived recently. A phase III vaccine trial that was conducted in Thailand (RV 144) using a recombinant canary pox vector (ALVAC) expressing clade E antigens of HIV-1 gp120 linked to the

transmembrane-anchoring portion of clade B gp41 and HIV-1 clade B *gag* and protease boosted with the AIDSVAX gp120 B/E (VaxGen) bivalent HIV-1 gp120 envelope showed a moderate efficacy of 31% in heterosexual Thais with a low risk for HIV infection [282, 316]. HIV-specific IFN- $\gamma$  ELISpot responses were demonstrated in 19.7% of vaccinees. The lymphoproliferation assay (LPA) response rate to gp120 was 87.3% and to gp120A244 90.1%. Binding antibodies to Env gp 120 developed in 98.6% of the vaccinees. An immunologic correlate of protection against HIV infection has not yet been reported.

## **2 RATIONALE OF THE STUDY**

Paper I and II: It is important to evaluate new and better assays as they become available in the markets in the context in which they will be used before adopting them in order to improve the diagnosis of HIV infection in resource-limited countries.

Paper III: High levels of recovery, viability and functionality of PBMCs are essential for reliable assessment of cell-mediated immune responses. The cell preparation technique best suited for use in two clinical trial sites: Stockholm, Sweden and Dar es Salaam, Tanzania was studied in preparation for the conduct of phase I/II HIV vaccine trials.

Paper IV: Analyses of cell-mediated immune responses are vital in the evaluation of HIV vaccine efficacy. Here we wanted to further define the HIV-1-specific lymphoproliferative responses in vaccinees in the HIVIS01/02 HIV-1 DNA prime-MVA boost vaccine trial in Stockholm by applying a flow cytometry-based assay employing either whole blood (FASCIA-WB) or PBMC (FASCIA-PBMC) to assess vaccine-induced CD4<sup>+</sup> and CD8<sup>+</sup> T-cell proliferation. We also explored the use of FASCIA especially suitable in isotope-restricted settings as an alternative to the conventional [<sup>3</sup>H]-thymidine uptake LPA.

Paper V: An effective and safe prophylactic HIV vaccine is urgently needed especially in many African countries where the incidence of HIV is high. A phase I/II HIV vaccine trial (HIVIS03) using an HIV-1 DNA prime-MVA boost regimen was conducted among healthy adults in Dar es Salaam, Tanzania with the aim of comparing id and im delivery of the DNA vaccine and to build capacity for clinical trials and establish methods for assessment of vaccine-induced immune responses on site.

## **3 OBJECTIVES**

### **3.1 Broad objective**

To improve methodologies for laboratory diagnosis of HIV infection suitable for use in developing countries and to monitor immune responses in a phase I and a phase I/II HIV-1 vaccine trial in Sweden and in Tanzania, respectively.

### **3.2 Specific objectives**

- Paper I: To evaluate the performance of two antibody ELISAs (Vironostika Uni-Form II plus O and Enzygnost anti-HIV-1/2 Plus) and two new diagnostic HIV antigen/antibody combination ELISAs (Murex and Vironostika HIV Uni-Form II antigen/antibody) for use in an alternative confirmatory HIV diagnostic testing strategy in Dar es Salaam, Tanzania.
- Paper II: To evaluate the performance of five simple rapid HIV assays and to formulate an alternative confirmatory strategy based on rapid HIV testing algorithms suitable for use in Tanzania.
- Paper III: To study techniques for blood mononuclear cell isolation best suited for use in two HIV vaccine trial sites: Stockholm, Sweden and Dar es Salaam, Tanzania.
- Paper IV: To compare different assays for the assessment of HIV-specific lymphoproliferative responses in a phase I trial in Sweden of healthy volunteers primed with HIV-1 DNA and boosted with recombinant HIV-1 MVA (HIVIS01/02).
- Paper V: To evaluate the safety and immunogenicity of a low dose id priming compared to a higher dose im priming with the HIVIS multigene, multiclade HIV-1 plasmid DNA vaccine followed by heterologous HIV-MVA boosting in a phase I/II clinical trial (HIVIS03) among healthy HIV negative volunteers in Dar es Salaam, Tanzania.



## **4 METHODS**

### **4.1 Paper I and Paper II**


In the study reported in paper I, we evaluated the performance of two HIV antibody ELISAs (Vironostika Uni-Form II plus O and Enzygnost anti-HIV-1/2 Plus) and two new diagnostic HIV antigen/antibody combination ELISAs (Murex and Vironostika HIV Uni-Form II antigen/antibody) for use in an alternative confirmatory HIV diagnostic testing strategy in Tanzania. The Enzygnost anti-HIV-1/2 Plus assay is made of recombinant HIV-1, HIV-2, and HIV-1 subtype O proteins while the Vironostika HIV Uni-Form II plus O assay consists of a mixture of HIV-1 p24, HIV-1 gp160, HIV-1 ANT70 peptide, and HIV-2 env peptide containing amino acids 592-603. The Murex and Vironostika antigen/antibody assays use anti-HIV-1 p24 monoclonal antibodies for both solid phase capture and probe conjugation for detection. We included a total of 1380 serum samples; 508 from blood donors, 511 from pregnant women and 361 from hospital patients between July 2003 and March 2004. The samples were left over after HIV testing/screening and were to be discarded. All ELISA reactive samples were tested on a confirmatory antibody assay, the Inno-Lia immunoblot assay (Innogenetics, Belgium).

In the Inno-Lia immunoblot assay, recombinant proteins and synthetic peptides from HIV-1 and HIV-2 and also a synthetic peptide from HIV-1 group O are coated as discrete lines on a plastic backed nylon strip. Five HIV-1 antigens are coated, namely sgp120 and gp41 which are specific for HIV-1, and p31, p24 and p17 which may also cross react with antibodies to HIV-2. Peptides from HIV-1 group O are present in the HIV-1 sgp120 line. The antigens gp36 and sgp105 are coated to detect specific antibodies to HIV-2. In addition four control lines are also coated on each strip: an anti-streptavidin line, a +/- cut-off line (human IgG), a 1+ positive control line (human IgG) and a 3+ strong positive control line which is also the sample addition control (anti-human Ig).

In the study reported in paper II, we evaluated five rapid HIV assays: Determine HIV-1/2 (Inverness Medical), SD Bioline HIV 1/2 3.0 (Standard Diagnostics Inc.), First Response HIV Card 1-2.0 (PMC Medical India Pvt Ltd), HIV1/2 Stat-Pak Dipstick (ChemBio Diagnostic System, Inc) and Uni-Gold HIV-1/2 (Trinity Biotech) between

June and September 2006 using 1433 whole blood samples from hospital patients, pregnant women, voluntary counseling and testing attendees and blood donors. All samples that were reactive on all or any of the five rapid assays and 10% of non-reactive samples were tested on a confirmatory Inno-Lia HIV I/II immunoblot assay (Innogenetics, Belgium).

Determine HIV-1/2 is a rapid immunochromatographic test for the qualitative detection of antibodies to HIV-1 and HIV-2. The sample is added to the sample pad. As the sample migrates through the conjugate pad, it reconstitutes and mixes with the selenium colloid-antigen conjugate. This mixture continues to migrate through the solid phase to the immobilized recombinant antigens and synthetic peptides at the patient window site. If antibodies to HIV-1 and/or HIV-2 are present in the sample, the antibodies bind to the antigen-selenium colloid and to the antigen at the patient window, forming a red line at the patient window site. If antibodies to HIV-1 and/or HIV-2 are absent, the antigen-selenium colloid flow past the patient window and no red line is formed at the patient window site. To insure assay validity, a procedural control bar is incorporated in the assay device.




**Figure 4. Determine HIV-1/2 test device. A shows control and patient bands; B shows control band only; C shows no band in control or patient bar and D shows patient band and no control band and is invalid**

(Source [www.determinetest.com/about\\_hiv.aspx](http://www.determinetest.com/about_hiv.aspx))

The SD BIOLINE HIV-1/2 3.0 is an immunochromatographic test for the qualitative detection of antibodies of all isotypes (IgG, IgM, IgA) specific to HIV-1 and HIV-2 in human serum, plasma or whole blood. The SD BIOLINE HIV-1/2 3.0 rapid test contains a membrane strip, which is precoated with recombinant HIV-1 capture antigen (gp41, p24) on test band 1 region and with recombinant HIV-1/2 capture antigen (gp36) on test band 2 region, respectively. The recombinant HIV-1/2 antigen (gp41,

p24 and gp36) - colloid gold conjugate and the specimen sample move along the membrane chromatographically to the test region (T) and form a visible line as the antigen-antibody-antigen gold particle complex forms with high degree of sensitivity and specificity. This test device has a letter of 1, 2 and C as Test Line 1 (HIV-1), Test Line 2 (HIV-2) and Control Line on the surface of the device. Both the Test Lines and Control Line in the result window are not visible before applying the sample. The Control Line is used for procedural control. The control Line should always appear if the test procedure is performed properly and the test reagents of Control Line are working.




**Figure 5. SD BIOLINE HIV-1/2 3.0 test device**  
**(Source [www. standardia.com](http://www.standardia.com))**

First Response HIV Card 1-2.0 is a rapid lateral-flow immunochromatographic test that can be performed on whole blood, serum, or plasma. The test requires only 10 uL of serum or 20 uL of whole blood as sample and one drop of developer solution. The results are obtained in 5 minutes. HIV1/2 Stat-Pak Dipstick assay is a single use, immunochromatographic screening test which uses a cocktail of antigens to detect antibodies to HIV-1 and 2 in serum, plasma or whole blood. The assay employs a combination of antibody binding protein, which is conjugated to colloidal gold dye particles, and antigens to HIV-1/2 which are bound to the membrane solid phase.


The Chembio HIV 1/2 STAT-PAK DIPSTICK is a single use, immunochromatographic screening assay which utilizes a cocktail of antigens to detect HIV-1 and HIV-2 antibodies in serum, plasma and whole blood. The assay employs a combination of antibody binding protein, which is conjugated to colloidal gold dye particles, and antigens to HIV1/2, which are bound to the membrane solid phase. The sample being tested and running buffer are applied to the sample pad. The running

buffer facilitates the lateral flow of the specimen through the membrane and promotes the binding of antibodies to the antigens. The antibodies if present bind to the gold conjugated antibody binding protein. In a reactive sample, the dye conjugated-immune complex migrates on the nitrocellulose membrane and is captured by the antigens immobilized in the test area producing a pink/purple line. In the absence of HIV-1/HIV-2 antibodies, there is no pink/purple line in the test area. The sample continues to migrate along the membrane and produces a pink/purple line in the control area containing immunoglobulin G antigens. The procedural control serves to show that specimens and reagents have been applied properly and have migrated through the test device.



**Figure 6. Chembio HIV 1/2 STAT-PAK DIPSTICK test device. A shows control and patient bands; B and C show control band only; D shows no band in control or patient bar and is invalid; and E shows patient band and no control band and is invalid (Source [www.chembio.com/humantest2.html](http://www.chembio.com/humantest2.html))**

The Uni-Gold™ HIV test was designed as a rapid immunoassay based on the immunochromatographic sandwich principle and is intended to detect antibodies to HIV-1 and HIV-2 in human serum, plasma and whole blood. The Uni-Gold™ HIV Test employs genetically engineered recombinant proteins representing the immunodominant regions of the envelope proteins of HIV-1 and HIV-2, glycoprotein gp41, gp120 (HIV-1), and glycoprotein gp36 (HIV-2). The recombinant proteins are immobilized at the test region of the nitrocellulose strip. These proteins are also linked to colloidal gold and impregnated below the test region of the device. A narrow band of the nitrocellulose membrane is also sensitized as a control region. During testing two drops of serum, plasma or whole blood is applied to the sample port, followed by two drops of wash buffer and allowed to react. Antibodies of any immunoglobulin class, specific to the recombinant HIV-1 or HIV-2 proteins will react with the colloidal gold linked antigens. The antibody protein-colloidal gold complex moves chromatographically along the membrane to the test and control regions of the test device. A positive result is visualized by a pink/red band in the test region of the device. A negative reaction occurs in the absence of detectable levels of human immunoglobulin antibodies to HIV-1 in the specimen; consequently no visible band develops in the test region of the device. Excess conjugate forms a second pink/red band in the control region of the device. The appearance of this band indicates proper performance of the reagents in the kit.



**Figure 7. Uni-Gold™ HIV test device. A shows control and patient bands; B shows control band only; C shows no band in control but patient bar and is invalid; and D shows neither control band nor patient band and is invalid**

**(Source [www.trinityusa.com](http://www.trinityusa.com))**

## 4.2 Paper III

Three techniques for the isolation of PBMC from heparinised blood were evaluated including standard Ficoll-Paque gradient centrifugation, the use of BD vacutainer cell preparation tubes (CPT) and the use of Greiner Bio-One LeucoSep tube techniques. Cell yield and viability were determined using a NucleoCounter (ChemoMetec A/S, Allerød, Denmark). The functionality of the purified PBMC was determined by IFN- $\gamma$  ELISpot testing using as antigen a pool of peptides from cytomegalovirus, Epstein-Barr virus and influenza virus (CEF).

## 4.3 Paper IV

HIV-specific lymphoproliferative responses were determined by different assays (Table 1) in the HIVIS01/02 phase I trial of an HIV-DNA prime MVA boost vaccine regimen conducted in Stockholm. The HIV DNA plasmids contained gp160 of HIV-1 subtypes A, B, and C, *rev* B, P17/p24 *gag* A and B and *RTmut* B. The MVA contained *env*, *gag* and *pol* of CRF01A\_E. The HIV-1 DNA vaccine was produced in Sweden by Professor Britta Wahren and collaborators at the Swedish Institute for Communicable Disease Control (SMI) and Karolinska Institute and the HIV-1 MVA vaccine was produced at the Walter Reed Army Institute for Research (WRAIR), Rockville, USA. The phase I trial of the vaccines was performed in Sweden in 40 volunteers. The trial took place at Venhälsan, Södersjukhuset Stockholm. The volunteers were randomized to 4 groups of 10 individuals each. Different modes of administration of the DNA vaccine were compared. The HIV-DNA was given with a needle-free injection device (biojector) id (1 mg) or im (3.8 mg) with or without GM-CSF at weeks 0, 4 and 12. The HIV-MVA boost was given id ( $10^7$  pfu) or im ( $10^8$  pfu) at month 9. Blood samples for immunological studies were collected prior to the first injection, on the day of injection, 2 weeks after the second and third HIV-DNA immunizations and 2 weeks after the HIV-MVA injection.

Lymphoproliferative responses to aldrithiol-2 (AT-2)-inactivated-HIV-1 antigen were tested by a [ $^3$ H]- thymidine uptake assay and a flow-cytometric assay of specific cell-mediated immune response in activated whole blood (FASCIA-WB) 2 weeks after the HIV-MVA boost. A FASCIA using PBMC (FASCIA-PBMC) was also employed (n=14). The methods and analysis used in the three LPAs are summarized in Tables 1 and 2.

**Table 1: Methods used in three HIV lymphoproliferation assays**

	<b>[<sup>3</sup>H]-thymidine uptake assay (n=38)</b>	<b>*FASCIA-WB (n=38)</b>	<b>*FASCIA-PBMC (n=14)</b>
Cell material	200 000 cells/well	Diluted whole blood in tubes (1/10)	200 000 cells/well
Stimuli	Aldrithiol-2 (AT-2) treated HIV-1 <sub>MN</sub>	Aldrithiol-2 (AT-2) treated HIV-1 <sub>MN</sub>	Aldrithiol-2 (AT-2) treated HIV-1 <sub>MN</sub>
Stimulation time	6 days	7 days	7 days
Processing	6 hour [ <sup>3</sup> H]-thymidine incorporation	Stained with anti-CD3 FITC and anti-CD4 PerCP	Stained with anti-CD3 FITC and anti-CD4 PerCP
Readout/Instrument	cpm/ Microbeta counter	Flow cytometric/ FACSCalibur or FACSCan	Flow cytometric/ FACSCalibur or FACSCan

\*Flow-cytometric Assay of Specific Cell-mediated Immune response in Activated whole blood [317].

**Table 2: Analysis used in three HIV lymphoproliferation assays**

	<b>[<sup>3</sup>H]-thymidine uptake assay (n=38)</b>	<b>*FASCIA-WB (n=38)</b>	<b>*FASCIA-PBMC (n=14)</b>
Analysis	Stimulation index (SI) = mean [ <sup>3</sup> H]-thymidine incorporation in antigen stimulated wells/mean incorporation in medium wells.	Mean percentage stimulation (%S): [100xtest-negative control/positive control-negative control]	Mean percentage stimulation (%S): [100xtest-negative control/positive control-negative control]
Cut-off determination	27 normal healthy controls	38 baseline values	17 normal healthy controls
	SI >8	CD4 <sup>+</sup> T-cells: %S >1.0 CD8 <sup>+</sup> T-cells: %S >1.1	CD4 <sup>+</sup> T-cells: %S >2.4 CD8 <sup>+</sup> T-cells: %S >2.8

\*Flow-cytometric Assay of Specific Cell-mediated Immune response in Activated whole blood.

#### **4.4 Paper V**

In the HIVIS03 phase I/II trial conducted in Dar es Salam the HIV-DNA and MVA vaccine constructs were the same as in the HIVIS01/02 trial. Sixty volunteers were recruited and randomized into three groups. Groups 1 and 2 were given id and im immunization modalities while group 3 which served as a control received placebo. Volunteers received three HIV-DNA/placebo vaccinations at months 0, 1 and 3 followed by two HIV-MVA/placebo boost vaccinations at month 9 and 21. HIV-1 specific cellular immune responses were determined by the IFN- $\gamma$  ELISpot assay using pools of overlapping HIV peptides representing Env, Gag and Pol proteins. LPA by [<sup>3</sup>H]-thymidine uptake was performed using four AT-2 treated HIV-1 antigens of four different clades. Four-colour ICS for assessment of Gag-specific IFN- $\gamma$ /IL-2 production was performed 2-4 weeks after the second HIV-MVA boost. Fresh PBMC were used for all cellular immunological assays. Serum binding antibody determination was performed using Advanced Biotechnologies native gp160 in an in house ELISA, Abbott Murex and Dade Behring Enzygnost Plus ELISAs and Inno-Lia immune blot assay. Nabs were measured using pseudoviruses and a luciferase based assay in TZM-bl cells as previously described [318]. The assay measures the reduction in luciferase reporter gene expression in TZM-bl cells with a single round of pseudovirus infection. A result  $\geq 50\%$  is considered to be a positive response. A PBMC assay employing an infectious molecular clone (IMC) that carries a LucR gene as a reporter was also used [319]. The percent neutralization by post-vaccination serum was calculated based on the level of virus growth in the presence of the same dilution of pre-vaccination serum and a result  $\geq 50\%$  was considered a positive response.

##### **4.4.1 Quality monitoring of PBMC purification technique and assays for the assessment of HIV-specific vaccine-induced immune responses in Tanzania**

Quality assurance program was strictly implemented to ensure accuracy and reliability of laboratory results for HIV-specific vaccine-induced immune responses in the HIVIS03 trial. All laboratory personnel were trained on the PBMC processing, cell counting, cryopreservation, thawing, IFN- $\gamma$  ELISpot assay, 4-colour ICS and [<sup>3</sup>H]-thymidine LPA assay at the SMI. They were validated and certified to perform the assays after proficiency assessment. Laboratory personnel who performed IFN- $\gamma$  ELISpot testing of cryopreserved PBMC from three donors in three consecutive runs with a mean coefficient of variation (CV) of  $<20\%$  was deemed validated. Internal



quality control procedures were performed including regular preventive maintenance of the lab equipments/instruments, use of pre-coated IFN- $\gamma$  ELISpot plates and pretested reagents such as RPMI, fetal calf serum and HIV-1 specific peptide pools and inclusion of known controls. In every IFN- $\gamma$  ELISpot assay run, phyto-haemagglutinin (PHA) (positive control), a peptide pool composed of cytomegalovirus (CMV), Epstein-Barr virus and influenza virus (CEF), a peptide pool of the pp65 protein of human CMV, normal human Tanzanian donor cells and RPMI medium only (negative control) were included. Staphylococcal enterotoxin A and B (SEAB), CEF and CMV peptide pools (positive controls) and RPMI medium only (negative control) were included in every 4-colour ICS assay run. In every [ $^3$ H]-thymidine LPA assay run, PHA (positive control), purified protein derivative (PPD), SUPTI and Jurkat Tat CCR5 microvesicles (control antigens) were also included. The Muhimbili University of Health and Allied Sciences (MUHAS) cellular immunology laboratory also performed IFN- $\gamma$  ELISpot proficiency testing every other month using HIV-1 infected donor cells with known reactivity patterns provided by SMI.

#### **4.5 Ethical considerations**

No ethical approval was required for Paper I because left over blood samples after routine HIV screening and removals of identifiers were used. Ethical approval was waived for paper II because left over blood samples after routine screening and without patient/client identifiers were used. Ethical approvals for Paper III, IV and V were obtained before the implementation of the clinical trials both in Sweden and in Tanzania. For paper III and V, MUHAS Senate Research and Publication committee, National Institute for Medical Research (NIMR) and Tanzania Food and Drug Authorities (TFDA) approved the studies. Written informed consents were obtained prior to recruitment of study volunteers.

## **5 RESULTS AND DISCUSSION**

### **5.1 Evaluation of HIV antibody and antigen/antibody testing strategies for the diagnosis of HIV infection (Paper I and II)**

Evaluation of various HIV-1 antibody detection assays using panels of American and European sera have shown that many of these tests have a high sensitivity and specificity [320]. However, early studies showed that some HIV antibody assays did not have a similar test performance when used for testing of African sera [321]. It is generally recommended to evaluate HIV-1 assays in the context in which they will be used before adopting them for wide-scale use [172]. After extensive evaluation of various HIV antibody ELISAs at MUHAS in Dar es Salaam in the early 1990s, an HIV testing strategy was adopted whereby serum samples that were reactive by an initial ELISA were tested by a second ELISA based on a different test principle and/or different antigens [187-188]. One of the HIV antibody tests which had been used in the testing strategy at MUHAS for more than 10 years, the Wellcozyme HIV-1 recombinant competitive ELISA was withdrawn from the market in 2004 which made it necessary to evaluate new HIV antibody ELISAs. Furthermore, new combined HIV antigen and antibody test kits had become available in the market including Vironostika Organon and Abbott Murex HIV test kits.

The evaluation of two HIV antibody ELISAs and two HIV antigen/antibody ELISAs reported in paper I showed that the sensitivity at initial testing was 100% (95% CI; 98.8-100%) for the Murex and Vironostika HIV Uni-Form II antigen/antibody and Enzygnost anti-HIV-1/2 Plus assays whereas Vironostika Uni-Form II plus O antibody ELISA showed one false negative sample at initial testing (99.7%; 95% CI; 98.2-99.9%) but 100% sensitivity after repeat testing. The specificity at initial testing was 99.8% (95% CI; 99.3-99.9%) for Enzygnost anti-HIV-1/2 Plus, 98.9% (95% CI; 98.1-99.4%) for each of the antigen/antibody combination ELISAs and 97.0% (95% CI; 95.8-97.8%) for Vironostika Plus O ELISA. The final specificity after repeat testing was 100% (95% CI; 99.7-100%) for Enzygnost anti-HIV-1/2 Plus, 99.4% (95% CI; 98.8-99.8%) for each of the antigen/antibody combination ELISAs and 97.9% (95% CI; 96.8-98.6%) for Vironostika Plus O ELISA. A combination of the two antigen/antibody ELISAs was not suitable for use in an alternative confirmatory HIV testing strategy since the serum samples which showed false positive reactions by these

two ELISAs were the same both at initial and repeat testing. Following this evaluation, we adopted at MUHAS an alternative confirmatory HIV testing strategy based on initial testing on Abbott Murex HIV antigen/ antibody ELISA followed by testing of reactive samples on the Enzygnost anti-HIV-1/2 Plus ELISA which gave 100% sensitivity and specificity. The discordant results between the two ELISAs were resolved by the Inno-Lia immunoblot assay. In Tanzania, ELISAs are used for laboratory diagnosis of HIV infection in some regional hospital and zonal laboratories, in the national blood transfusion services and at the Muhimbili National Hospital laboratory. The Vironostika HIV Uni-Form II antigen/antibody assay and the Enzygnost anti-HIV-1/2 Plus ELISA were adopted for the screening of blood and blood products in the national and zonal blood transfusion service centres in Tanzania. Recently, the Enzygnost anti-HIV-1/2 Plus ELISA has been phased out from the market and the fourth-generation Enzygnost HIV Integral II ELISA (Siemens Healthcare Diagnostics Products GmbH, Germany) has been introduced. An evaluation of the Enzygnost HIV Integral II ELISA using Tanzanian serum samples from different populations is warranted.

In a recently reported study from Japan, initial screening of serum samples from 6461 pregnant women by the Enzygnost HIV Integral antigen/antibody ELISA showed a specificity of 99.6%. Sequential testing of the samples reactive on this ELISA by another fourth generation ELISA, the VIDAS HIV DUO Quick ELISA resulted in 100% specificity [322]. In the evaluation reported in paper I, we did not detect any sample that was HIV antigen positive but HIV antibody negative. We instead used one seroconversion panel (AU PRB945) to determine the ability to detect acute HIV infection. Abbott Murex HIV antigen/antibody ELISA detected acute HIV infection 13 days after the first bleed and Vironostika HIV antigen/antibody ELISA 15 days after the first bleed. The study conducted in pregnant women in Japan revealed that HIV infection was detected with the VIDAS HIV DUO Quick ELISA earlier than with the Enzygnost HIV Integral ELISA in eight out of ten HIV-1 seroconversion panels with an average interval of 4.5 days [322]. It was reported further that VIDAS HIV DUO Quick ELISA was 16-32 times more sensitive for antigen detection than the Enzygnost HIV Integral ELISA when using serial two-fold dilutions of three HIV-1 antigen samples [322]. In a recent study, the analytical sensitivity of four HIV antigen/antibody assays (ARCHITECT HIV Ag/Ab Combo, AxSYM HIV Ag/Ab Combo, VIDAS HIV

DUO Quick and VIDAS HIV DUO Ultra) and one p24 assay, most commonly used in France was evaluated using the p24 WHO standard [323]. Four of the five assays had a lower limit of detection below 2 IU/ml (1.24 IU/ml for ARCHITECT HIV Ag/Ab Combo, 0.66 IU/ml for VIDAS HIV DUO Ultra, 0.43 IU/ml for VIDAS HIV DUO Quick and 0.73-1.15 IU/ml for VIDAS p24) while that of AxSYM was close to 2 IU/ml [323] showing that VIDAS HIV DUO Quick ELISA performed best to detect acute HIV infection compared to the other assays. It is important to note that the international (WHO standard) is based on a subtype B isolate and there might be subtype variations in antigen detection.

Following an evaluation of simple rapid HIV antibody assays at MUHAS several years ago, a rapid HIV testing algorithm was adopted which consisted of initial screening with the Capillus assay followed by confirmatory testing of reactive samples with the Determine assay [198]. However, the Capillus assay required cold storage making it unsuitable for use in peripheral areas where electricity is not readily available or in settings where power outages are frequent. Dependency for the cold chain by Capillus, need to scale up access to HIV screening, diagnosis and treatment together with availability of newer HIV rapid tests in the market made it necessary to embark on new evaluations of rapid HIV assays aiming at developing alternative HIV testing algorithms for use in Tanzania.

Our recent evaluation of five rapid HIV assays included 390 confirmed HIV-1 antibody positive samples, and 1043 HIV seronegative samples (Paper II). We found that the sensitivity at initial testing of Determine, SD Bioline and Uni-Gold was 100% (95% CI; 99.1-100) while First Response and Stat-Pak had a sensitivity of 99.5% (95% CI; 98.2-99.9) and 97.7% (95% CI; 95.7-98.9), respectively, which increased to 100% (95% CI; 99.1-100) on repeat testing. The initial specificity of the Uni-Gold assay was 100% (95% CI; 99.6-100) while specificities were 99.6% (95% CI; 99-99.9), 99.4% (95% CI; 98.8-99.7), 99.6% (95% CI; 99-99.9) and 99.8% (95% CI; 99.3-99.9) for Determine, SD Bioline, First Response and Stat-Pak assays, respectively. There was no sample which gave concordantly false positive results in Uni-Gold, Determine and SD Bioline assays. The Tanzanian Ministry of Health and Social Welfare has adopted a rapid HIV testing algorithm based on our study results which includes initial testing on SD Bioline assay followed by testing of reactive samples on the Determine assay which

had a sensitivity of 100% and specificity of 100% with Uni-Gold as tiebreaker for discordant results. This rapid HIV testing algorithm is currently being used for diagnosis of HIV infection in the VCT, PMTCT and HIV CTC clinics.

Problems with the HIV diagnostic accuracy when using rapid HIV tests in non-laboratory settings have been encountered in African studies. In a screening study of 1517 males for trials of circumcision for HIV prevention in rural Uganda, an algorithm using initial testing with the Determine test followed by testing of reactive samples with the Stat-Pak assay and further testing with Uni-Gold to resolve discordant results showed a sensitivity of 97.7% and a low specificity of 94.1%. Exclusion of results with weak positive bands increased the specificity to 99.6% [180]. In our evaluation, the rapid testing algorithm that included initial testing on Determine followed by testing of reactive samples on Stat-Pak Dipstick assay showed a 100% sensitivity and specificity with no concordant false positive results (Paper II). Another study of rapid assays including Determine, Uni-Gold and Capillus used for voluntary counseling and testing of more than 6000 individuals in Uganda and Kenya showed that the sensitivity and specificity of rapid assays varied significantly across sites with a high rate of false positives in Uganda (positive predictive values ranging from 45.7% to 86.62%) [181]. A recent study of rapid HIV assays among pregnant women in a clinical setting in South Africa showed that First Response, Standard Diagnostic and Pareekshak rapid HIV tests which performed well under laboratory conditions showed poor sensitivity (94.5%, 87.5% and 90.2%, respectively) when used in the clinical setting [182].

Two fourth-generation rapid HIV assays based on the detection of both HIV antigen and antibody have been developed and introduced in the market. The Immunocomb Trispot (Orgenics, Yavne, Israel) was first introduced but to our knowledge no independent evaluation reports have been published. The more recently introduced Determine HIV-1/2 antigen/antibody Combo is an immunochromatographic test for the qualitative detection of p24 antigen and antibodies to HIV-1 and HIV-2. A recent evaluation of Determine HIV-1/2 Combo assay using serial serum panels including among others an HIV seroconversion panel and primary HIV infection samples showed 100% antibody sensitivity and 100% antibody specificity [324]. The antigen sensitivity of the assay was found to be 86.6% compared to a reference single antigen ELISA. However, the assay could not detect antigen in one group O, one subtype F and two subtype H cell supernatant isolates and none of the HIV-2 antigen could be detected

[324]. The assay is proposed as an alternative for antigen detection in the diagnosis of HIV infection in high-risk populations and blood donor screening in resource-limited settings.

## **5.2 Processing of blood mononuclear cells for use in HIV vaccine trials (Paper III)**

The HIVIS01/02 HIV-1 DNA prime MVA boost phase I vaccine trial was conducted in Stockholm in 2005 and 2006 [304] and the phase I/II HIVIS03 trial using the same vaccine constructs was conducted in Dar es Salaam from 2007 to 2010 (Paper V). The primary immunogenicity endpoint in these trials was the determination of HIV-specific cell-mediated immune responses by the IFN- $\gamma$  ELISpot assay. Before the start of these vaccine trials, procedures for the isolation of PBMC were tested at each of the two trial sites to find the techniques best suited for use at the respective sites (Paper III). In our evaluation of cell separation procedures, we found no differences in mean recovery or mean viability of fresh PBMC purified by Ficoll-Paque gradient centrifugation and CPT techniques used in Stockholm. In Dar es Salaam, recovery of PBMC isolated by Ficoll-Paque gradient technique was higher compared to CPT ( $1.58 \pm 0.6$  vs.  $1.34 \pm 0.4$  million cells/mL blood,  $p=0.0469$ ) and the viability of PBMC processed by Ficoll-Paque gradient was higher compared to CPT purified cells ( $95.8 \pm 2.3$  vs.  $92.6 \pm 4.8$  %,  $p=0.0081$ ). Furthermore, LeucoSep cell separation gave a higher yield ( $1.10 \pm 0.3$  vs.  $0.92 \pm 0.3$  million cells/mL blood,  $p=0.0022$ ) and viability ( $95.7 \pm 2.0$  vs.  $93.4 \pm 3.2$  %,  $p=0.0012$ ) than Ficoll-Paque cell separation. The studies in Stockholm as well as in Dar es Salaam of the functionality of purified PBMC showed no difference in the rates of responses to a CEF peptide pool in the IFN- $\gamma$  ELISpot assay for the pair-wise comparisons of the different cell separation techniques. Following these evaluations, the CPT technique was adopted for use at the SMI while the LeucoSep cell separation technique is being used at MUHAS.

A recent study in Uganda of PBMC separation by LeucoSep processing of blood samples from a large number of HIV-uninfected individuals showed a yield of  $1.3 \times 10^6$  cells per mL of whole blood and 97% viability which is similar to our findings in Tanzanian individuals [325]. It has been recommended that PBMC separation should yield  $1-2 \times 10^6$  cells/mL of whole blood in which approximately 60%-70% of mononuclear cells are lymphocytes with >95% viability [326]. In most HIV vaccine trials cryopreserved cells have been used for monitoring of vaccine-induced cellular

immune responses. In the HIV-1 DNA prime MVA boost vaccine trials in Sweden and in Tanzania, we have primarily used fresh PBMC for assessment of vaccine-induced cellular immune responses. However, PBMCs from the volunteers in these trials have also been cryopreserved for subsequent additional cellular immunological studies.

### **5.3 Assessment of HIV vaccine-induced lymphoproliferative responses (Paper IV)**

In the HIVIS01/02 phase I HIV vaccine trial that was conducted in Stockholm, Sweden, vaccine-induced cell-mediated immune responses were monitored by the IFN- $\gamma$  and the IL-2 ELISpot assays and by LPA. After receipt of three HIV-DNA immunizations and one HIV-MVA boosting immunization, 34 of 37 (92%) vaccinees had HIV-specific IFN- $\gamma$  ELISpot responses and 25 (68%) had positive IL-2 responses. Thirty-five of 38 (92%) vaccinees were reactive by the conventional [ $^3$ H]-thymidine uptake assay [304]. In the study reported in paper IV, the HIV-specific lymphoproliferative responses in these vaccinees were further assessed by a flow cytometry LPA with simultaneous CD4<sup>+</sup> and CD8<sup>+</sup> T-cell immunophenotyping using either whole blood (FASCIA-WB) or PBMC (FASCIA-PBMC). Thirty-two of 38 (84%) vaccinees were reactive by the CD4<sup>+</sup> T-cell FASCIA-WB, and 7 of 38 (18%) also exhibited CD8<sup>+</sup> T-cell responses. There was a strong correlation between the proliferative responses measured by the [ $^3$ H]-thymidine uptake assay and CD4<sup>+</sup> T-cell FASCIA-WB ( $r=0.68$ ;  $P < 0.01$ ). Fourteen vaccinees were analyzed using all three assays. Ten of 14 (71%) and 11/14 (79%) demonstrated CD4<sup>+</sup> T-cell responses in FASCIA-WB and FASCIA-PBMC, respectively. CD8<sup>+</sup> T-cell reactivity was observed in 3/14 (21%) and 7/14 (50%) using the FASCIA-WB and FASCIA-PBMC, respectively. All 14 were reactive by the [ $^3$ H]-thymidine uptake assay. It was concluded that FASCIA-PBMC may be an alternative to the [ $^3$ H]-thymidine uptake assay for assessment of vaccine-induced T-lymphocyte proliferation especially in radioactive-restricted settings.

Another flow cytometric assay based on the use of carboxyfluorescein diacetate succinimidyl ester (CFSE) to monitor lymphocyte division has been reported to be an effective method to measure T-lymphocyte proliferation [306, 327-329]. CFSE is a fluorescein-based dye compatible with a wide range of fluorochromes making its application possible in multi-color flow cytometry. Recently, a comparison of three LPAs including [ $^3$ H]-thymidine uptake, FASCIA PBMC which has been renamed flow

cytometry LPA (FC-LPA) and CFSE was performed to monitor the HIV-1-specific vaccine-induced T-cell responses in 24 vaccinees in the HIVIS05 trial [330]. In this trial, 24 vaccinees from the former HIVIS01/02 trial were recruited to receive a second HIV-MVA boost three years after the first HIV-MVA boost. Using the FC-LPA, CD4<sup>+</sup> T-cell responses were detected in 100% of the vaccinees and CD8<sup>+</sup> T-cell responses in 82% two weeks after the second HIV-MVA. The CFSE also revealed both CD4<sup>+</sup> and CD8<sup>+</sup> HIV-specific T-cell proliferation. However, the FC-LPA detected more CD4<sup>+</sup> T-cell responses than the CFSE assay (100% vs. 71%). There was a good correlation between the proliferative responses assessed by the <sup>3</sup>H-thymidine uptake and FC-LPA-CD4 ( $r=0.66$ ;  $p<0.01$ ), and by <sup>3</sup>H-thymidine uptake and the CFSE-CD4 ( $r=0.53$ ;  $p<0.05$ ). There was also a significant correlation between FC-LPA-CD4 and CFSE-CD4 ( $r=0.52$ ;  $p<0.01$ ) [330]. There are plans to use FC-LPA for assessment of vaccine-induced T-lymphocyte proliferation in the HIV-DNA-MVA vaccine trials at the National Health Institute in Maputo, Mozambique where the use of isotopes is not permitted.

#### **5.4 Monitoring of immune responses in healthy individuals immunized with HIV-1 DNA and boosted with recombinant MVA (HIVIS03) (Paper V)**

Preparations have been made for HIV-1 vaccine trials in humans in Tanzania since 1994. These preparations have included studies of a potential cohort for vaccine trials, consisting of police officers in Dar es Salaam [331], determination of prevalent HIV-1 subtypes in Dar es Salaam (subtypes A, C and D) [50], training of laboratory and clinical personnel, and transfer of virological and immunological methods to the MUHAS laboratories in Dar es Salaam from the collaborating laboratories in Stockholm. The HIVIS 01/02 trial in Stockholm, Sweden informed the design of the subsequent phase I/II HIV vaccine trial (HIVIS03) in Dar es Salaam, Tanzania. In the HIVIS03 trial, HIV-1 DNA vaccinations were given id or im without GM-CSF, the HIV-1 MVA boosting vaccinations were administered im at  $10^8$  pfu and volunteers recruited were younger than 40 years of age. The main aim of the HIVIS03 trial was to explore if priming with a low id dose of HIV-DNA was superior to a higher dose of HIV-DNA given im for eliciting strong and broad HIV-specific cellular immune responses after HIV-MVA boosting.



In the HIVIS03 trial, two weeks after the third HIV-DNA injection, 22/38 (58%) vaccinees had IFN- $\gamma$  ELISpot responses to Gag (Paper V). Two weeks after the first HIV-MVA boost, all of 35 (100%) vaccinees responded to the Gag and 31 (89%) to Env. Two to four weeks after the second HIV-MVA boost, 28/29 (97%) vaccinees had IFN- $\gamma$  responses, 27 (93%) to Gag and 23 (79%) to Env. After the first HIV-MVA boost all 35 (100%) vaccinees responded to Gag WR peptide pool while among 29 vaccinees after the second HIV-MVA boost, 23 (79%) had positive responses to Gag WR and 3 had positive responses to Gag II and one to Gag I. IFN- $\gamma$  ELISpot responses to Gag WR were significantly higher after the first than after the second HIV-MVA boost. The id-primed recipients had significantly higher responses to Env but not to Gag than im recipients. There were more volunteers with responses to multiple peptide pools in the id group than in the im group. Four weeks after the second HIV-MVA boost, ICS for Gag-specific IFN- $\gamma$ /IL-2 production showed both CD8<sup>+</sup> and CD4<sup>+</sup> T-cell responses. Two weeks after the first and the second HIV-MVA boost, all of 32 and all of 25 vaccinees had HIV-specific lymphoproliferative responses, respectively. It was concluded that the HIV-1 DNA prime/MVA boost was safe and highly immunogenic among healthy Tanzanian volunteers. Furthermore, the low dose id multigene multiclade HIV-DNA elicited higher and broader cellular immune responses to Env compared to a higher dose administered im after boosting with HIV-MVA.

The 100% HIV-specific IFN- $\gamma$  ELISpot response rate found in the HIVIS03 trial is higher than that reported in other trials of HIV-DNA prime and poxvirus or rAd5 boost regimens [309-310]. The magnitude of the IFN- $\gamma$  ELISpot responses was also higher in the HIVIS03 responders compared to that in HIV-DNA prime poxvirus or rAd5 boost trials [309-310]. In the HIVIS03 trial, the response rate and magnitude of the IFN- $\gamma$  ELISpot responses were higher to Gag than to Env but the frequency of Env responses was also high (89%). In other trials of HIV-DNA prime and poxvirus or rAd5 boost regimens, IFN- $\gamma$  ELISpot responses to Env predominated [309-310]. However, a recent trial of Geovac HIV-DNA and MVA vaccines (HVTN 065) showed that CD4<sup>+</sup> T-cell responses measured by ICS were evenly distributed between Gag and Env after two HIV-DNA immunizations followed by two HIV-MVA boosts [307]. The CD8<sup>+</sup> T-cell response rate to Gag and Env was also similar. Gag-specific cellular immune responses may be important for vaccine-induced protection since these responses have been shown to be associated with low viral loads in HIV-infected individuals [148-149].

In the HIVIS03 trial, lymphoproliferative responses to HIV-1 antigens of various clades including B, A, C and /A\_E were also tested [332]. Two weeks after the first HIV-MVA boost, all of 32 (100%) vaccinees had strong positive lymphoproliferative responses to HIV-1 antigens from all four clades. Two weeks after the second HIV-MVA boost, all of 25 (100%) vaccinees showed positive lymphoproliferative responses to each of the AT-2-treated HIV-1 antigens of clades B, A, A\_E and all except one vaccinee showed reactivity to the clade C antigen. Six months after the second HIV-MVA boost, 16 out of 18 (88.9%) vaccinees still had positive lymphoproliferative responses to HIV-1 antigens of clades B and A\_E, while 14 (77.8%) and 13 (72.2%) vaccinees had positive lymphoproliferative responses to HIV-1 antigens of clades A and C, respectively [332]. Thus the HIV DNA-MVA vaccine approach induced strong and durable HIV-specific lymphoproliferative responses with a high degree of cross-clade reactivity.

In the HIVIS03, IFN- $\gamma$  ELISpot and 4-colour ICS assays and the LPA were performed to monitor the HIV-specific vaccine-induced immune responses using fresh cells. Additional studies of vaccine-induced immune responses in the HIVIS03 trial will be performed using cryopreserved cells including epitope mapping of IFN- $\gamma$  ELISpot responses and ICS for assessment of polyfunctional cytokine production by CD4<sup>+</sup> and CD8<sup>+</sup> T-cells and the expression of cytolytic markers in these cells. In the HIVIS05 trial, HIV-Gag specific immune responses have been assessed by 8-colour ICS for expression of cytokines (CD3/CD4/CD8/IFN- $\gamma$ /IL-2/TNF- $\alpha$ /MIP1- $\beta$ /VIVID). Polyfunctional CD4<sup>+</sup> and CD8<sup>+</sup> T-cell Gag-specific responses were detected in vaccinees who had IFN- $\gamma$ -ELISpot Gag reactivity >175 SFC/million PBMC (unpublished data).

In the HIVIS03 trial, none of the vaccinees or placebo recipients was positive in the diagnostic HIV serological assays after three HIV-DNA immunizations or after the first HIV-MVA boost. However, four weeks after the second HIV-MVA boost, all 30 vaccinees (100%) were positive in the diagnostic HIV antigen/antibody (Abbott Murex, UK) and the Enzygnost anti-HIV-1/2 Plus (Dade Behring, Germany) ELISAs and in the Inno-Lia immunoblot assay. Seven out of 33 (21%) and 26 of 29 (90%) vaccinees had antibodies against gp160 in an in house ELISA after the first and second HIV-MVA boost, respectively. A recent follow up of HIVIS03 trial volunteers showed that

27 out of 27 (100%) and 26 of 26 (100%) vaccinees were still reactive in the Murex (Abbott Murex, UK) and Integral (Siemens, Germany) HIV antigen/antibody ELISAs, respectively, 17 to 22 months after the second HIV-MVA boost. Furthermore, on the Inno-Lia immunoblot (Inno-genetics, Belgium) assay, 19 out of 27 (70%) vaccinees fulfilled the diagnostic criteria for seropositivity and 8 were indeterminate. All of 27 (100%) vaccinees reacted against Gag and 19 out of 27 (70%) reacted against Env (gp120 or gp41) on Inno-Lia. Testing by the Roche HIV-1 DNA PCR assay excluded HIV-1 infection in all these volunteers.

Testing of sera from 29 vaccinees in the HIVIS03 trial 4 weeks after the second HIV-MVA boost for HIV Nabs was performed in collaboration with WRAIR using both PBMC and TZM-bl based assays. There was no demonstrable neutralizing activity in the TZM-bl pseudovirus assay using CM235 clade CRF01\_AE, GS015 clade C and BaL clade B pseudoviruses. In contrast, a high antibody response rate was demonstrated using the PBMC assay. The response rates were higher against the CM235 clade CRF01\_AE virus (overall 24/29, 83%) and the SF162 clade B virus (21/29, 72%) as compared to the BaL clade B virus (9/29, 31%). The response rate was not significantly different between id versus im HIV-DNA primed vaccinees ( $p=0.43$ ). The observation that HIV antibodies can be inhibitory using a PBMC target cell assay, but non-functional in a cell line based pseudovirus assay has been reported in previous studies [48, 333-335], but has not been reported previously using human vaccine sera. The mechanism for the inhibitory activity in the PBMC assay employed in our study is currently under investigation.

The HVTN 065 trial showed that the frequency of Env binding and Nabs to HIV-1 isolates was higher after three HIV-rMVA immunizations than after two HIV-DNA immunizations followed by two HIV-rMVA boosts [307]. These findings suggest that further boosting with HIV-MVA of HIVIS03 vaccinees could improve HIV-specific humoral immune responses.

Based on the HIVIS03 findings, a phase II trial, Tanzania and Mozambique HIV Vaccine Programme (TaMoVac I) started in May 2010 to explore further the optimal HIV-1 DNA vaccine delivery method. The primary objectives of the TaMoVac I are to determine the safety and immunogenicity of three immunizations with HIVIS-DNA at a dose of 600 µg or 1000 µg administered id followed by two MVA-CMDR

boosting immunizations in. Two clinical trial sites, Dar es Salaam and Mbeya in Tanzania participate in the TaMoVac I trial, each with enrolment of 60 volunteers with low risk for HIV acquisition. It is also planned in collaboration with the AfreVac group to further boost vaccinees with gp140 after two HIV-MVA boosts to enhance humoral immune responses. Furthermore, a new trial, TaMoVac II is planned to start in 2012 in Tanzania and Mozambique with the objectives to document further the immunogenicity and safety of the HIVIS DNA/MVA immunogens and to introduce novel delivery technologies of the HIVIS DNA vaccine such as electroporation to try to induce long term memory and enhance antibody production.

## 6 CONCLUSIONS

We have evaluated alternative serological HIV testing strategies based on the testing by HIV ELISAs and rapid HIV assays for the laboratory diagnosis of HIV infection in resource-limited settings. An alternative confirmatory HIV ELISA testing strategy has been adopted at MUHAS in Dar es Salaam and in the national blood transfusion services in Tanzania. The evaluation of various combinations of rapid HIV assays has resulted in formulation of a national confirmatory rapid HIV testing algorithm which has been adopted for use in VCT, PMTCT and HIV CTC clinics throughout Tanzania.

Testing of various procedures for optimal preparation of PBMC for use in HIV vaccine trials in Sweden and Tanzania, respectively, led to the adoption of different cell separation techniques in the two clinical trial sites.

Following investigation of three lymphoproliferative assays for monitoring of vaccine-induced immune responses in a phase I HIV-DNA prime and MVA boost trial in Stockholm, we concluded that a flow-cytometric assay using PBMC could be useful as an alternative to the [<sup>3</sup>H]-thymidine uptake assay for assessment of HIV vaccine-induced T-cell proliferation, especially in isotope-restricted settings. Furthermore, the flow-cytometric assay has the advantage of allowing CD4<sup>+</sup> and CD8<sup>+</sup> T-cell immunophenotyping of the proliferating cells.

In a phase I/II HIV vaccine trial (HIVIS03) in Dar es Salaam, Tanzania, we found that the HIV-DNA prime MVA boost vaccine approach was safe and highly immunogenic eliciting HIV-specific cellular immune responses and binding antibody responses in 100% of the vaccinees. Furthermore, a high neutralizing antibody response rate was demonstrated using a PBMC assay. Capacity has been built by training of human resources, acquisition of laboratory equipments/instruments, establishment of assays for monitoring of vaccine-induced immune responses and experience of conducting an HIV vaccine trial. Capacity built through the HIVIS03 trial paved the way for the funding of the follow-up phase II HIV vaccine trials, TaMoVac I and II in Tanzania and Mozambique with aims to explore further the HIV-DNA prime MVA boost vaccine regimen for possible phase IIb or III HIV vaccine trials in the future.

## **7 ACKNOWLEDGEMENTS**

I would first like to thank all the volunteers for participating in these studies. This work would not have been possible without your participation. I would also like to thank:

Prof. Gunnel Biberfeld, my supervisor for your guidance, encouragement and support during my training. You have always been enthusiastic to my work, committed and dedicated to your supervision. You are a great researcher and teacher, and I have learnt a lot from you.

Prof. Fred Mhalu, my co-supervisor for your guidance, supervision and support. You are a committed and dedicated biomedical scientist in the field of HIV and AIDS in Africa who sacrificed your time and energy for the scientific endeavors. The bilateral research and training program between MUHAS and KI under your coordination together with Gunnel Biberfeld has been a great success story.

Prof. Eligius Lyamuya, my co-supervisor for your guidance, supervision and support. You have been my mentor and academic supervisor since 1996 when I was M.Phil. program student at the University of Bergen in Norway. You have been my role model and I have always admired your professionalism, expertise and passion.

Dr. Soren Anderson, my co-supervisor for your supervision and support.

Dr. Charlotta Nilsson, Dr. Karina Godoy, Katarina Karlen, Linda Jernberg, Eda Ericksson for facilitating my laboratory training at SMI. I cannot thank you enough for your great support. Anita Ostborn, for your great assistance with logistics during my visits and stay in Stockholm. You have all been friendly and kind to me.

Prof. Eric Sandstrom, Prof. Britta Wahren, Prof. Peter Biberfeld, Andreas Brave and Bo Hejdeman for your support, scientific advice and encouragement.

Nelson Michael, Mary Marovich, Merlin Robb, Mark de Souza, and other collaborators at WRAIR for support, sharing your scientific expertise and experiences for the conduct of HIVIS01/02 and HIVIS03 trials.

Swedish International Development Cooperation Agency (Sida) for financial support for my training, EU and EDCTP for funding the HIVIS01/02 and HIVIS03 trials.

SMI administration for support and provision of necessary logistics during my training.

MUHAS administration led by the Vice Chancellor Prof. Kisali Pallangyo for granting me permission and for the support to pursue the training.

Head, Department of Microbiology and Immunology, Prof. Mecky Matee, for support and encouragement.

Prof. Muhammad Bakari, a senior colleague and study director of the HIVIS03 who encouraged me to join the bilateral Sida research and training, for the support and guidance.

The former and the current MUHAS HIVIS03 laboratory staff, Emanuel Salala, Fauster Mgya, Eleonora Haule, Zakaria Mtulo, Colman Mchau, Magdalena Kasya, Andrew Sapula, Scolastica Mahundi, Viola Msangi and Judica Mbwana for hard work and a great spirit of team work that enabled successful completion of the studies.

MUHAS/MNH HIVIS03 clinical team, Prof. Muhammad Bakari, Prof. Mohamed Janabi, Dr. Eric Aris, Dr. Serafina Mkuwa, Dr. Joel Francis, Deus Buma, Lugano Kabadi, Mary Ngatoluwa, Tumaini Massawa, Dorothea Niima and Gladness Kiwelu for continued efforts and a great spirit of team work that enabled successful completion of the studies.

Prof. Karim Manji, Prof. Ferdinand Mugusi, Prof. Sylvia Kaaya, Prof. Willy Urassa, Prof. Zul Premji, Prof. Japhet Killewo, Prof. Wafaie Fawzi and Prof. Chris Duggan for great support and encouragement.

Dr. Amos Mwakigonja, Dr. Matilda Ngarina-mosi, Dr. Charles Kilewo, Dr. Daudi Simba, Dr. Sabrina Moyo, Dr. Mabula Kasubi, Dr. Fausta Mosha, Dr. Patricia Munseri, Dr. Edith Tarimo, Dr. Agricola Joachim and the entire MUHAS/Harvard research laboratory team for support and encouragement.

My family: my mother Masaad Salim Magram and late father Aboud Said Saleh for love and caring, support and encouragement to get education and to progress my career. The best of me, I owe to you my parents. My sisters, Latifa, Sharifa and Saloha, for love, consistent support and encouragement during training. My two lovely daughters, Saloha and Sharifa, you have been my great inspiration. The times I have been away from home were spent for a good course. I will always support and guide you to achieve anything you set your minds to. My cousin sister Nuru and my niece, Masaad, for support and encouragement. Finally, to my loving wife, Nasra, for love, daily support and encouragement. I cannot thank you enough for tolerance and hardships you have experienced especially when I am away from home. You have always been there for me.

## 8 REFERENCES

1. CDC, *Kaposi's sarcoma and Pneumocystis pneumonia among homosexual men--New York City and California*. MMWR Morb Mortal Wkly Rep, 1981. **30**(25): p. 305-8.
2. Gottlieb, M.S., et al., *Pneumocystis carinii pneumonia and mucosal candidiasis in previously healthy homosexual men: evidence of a new acquired cellular immunodeficiency*. N Engl J Med, 1981. **305**(24): p. 1425-31.
3. Barre-Sinoussi, F., et al., *Isolation of a T-lymphotropic retrovirus from a patient at risk for acquired immune deficiency syndrome (AIDS)*. Science, 1983. **220**(4599): p. 868-71.
4. Gallo, R.C., et al., *Frequent detection and isolation of cytopathic retroviruses (HTLV-III) from patients with AIDS and at risk for AIDS*. Science, 1984. **224**(4648): p. 500-3.
5. Clavel, F., et al., *Isolation of a new human retrovirus from West African patients with AIDS*. Science, 1986. **233**(4761): p. 343-6.
6. Albert, J., et al., *A new human retrovirus isolate of West African origin (SBL-6669) and its relationship to HTLV-IV, LAV-II, and HTLV-IIIb*. AIDS Res Hum Retroviruses, 1987. **3**(1): p. 3-10.
7. Jaffe, H.W., D.J. Bregman, and R.M. Selik, *Acquired immune deficiency syndrome in the United States: the first 1,000 cases*. J Infect Dis, 1983. **148**(2): p. 339-45.
8. Butto, S., et al., *Laboratory diagnostics for HIV infection*. Ann Ist Super Sanita, 2010. **46**(1): p. 24-33.
9. UNAIDS, *UNAIDS report on the global AIDS epidemic 2010*. UNAIDS/10.11E/JC1958E, November 2010. At [http://www.unaids.org/globalreport/documents/20101123\\_GlobalReport\\_full\\_e\\_n.pdf](http://www.unaids.org/globalreport/documents/20101123_GlobalReport_full_e_n.pdf).
10. WHO, *Towards universal access: scaling up priority HIV/AIDS interventions in the health sector: progress report 2010*. At [http://whqlibdoc.who.int/publications/2010/9789241500395\\_eng.pdf](http://whqlibdoc.who.int/publications/2010/9789241500395_eng.pdf).
11. Mhalu, F., et al., *Prevalence of HIV infection in healthy subjects and groups of patients in Tanzania*. AIDS, 1987. **1**(4): p. 217-21.
12. Dolmans, W.M., et al., *Prevalence of HIV-1 antibody among groups of patients and healthy subjects from a rural and urban population in the Mwanza region, Tanzania*. AIDS, 1989. **3**(5): p. 297-9.
13. Killewo, J., et al., *Prevalence of HIV-1 infection in the Kagera region of Tanzania: a population-based study*. AIDS, 1990. **4**(11): p. 1081-5.
14. Kigadye, R.M., et al., *Sentinel surveillance for HIV-1 among pregnant women in a developing country: 3 years' experience and comparison with a population serosurvey*. AIDS, 1993. **7**(6): p. 849-55.
15. Killewo, J.Z., et al., *Incidence of HIV-1 infection among adults in the Kagera region of Tanzania*. Int J Epidemiol, 1993. **22**(3): p. 528-36.
16. Mnyika, K.S., et al., *Prevalence of HIV-1 infection in urban, semi-urban and rural areas in Arusha region, Tanzania*. AIDS, 1994. **8**(10): p. 1477-81.
17. Kwesigabo, G., J.Z. Killewo, and A. Sandstrom, *Sentinel surveillance and cross sectional survey on HIV infection prevalence: a comparative study*. East Afr Med J, 1996. **73**(5): p. 298-302.
18. Petry, K.U. and H. Kingu, *HIV infection among pregnant women in Lindi, Tanzania, 1989-1993*. Int J STD AIDS, 1996. **7**(4): p. 265-8.
19. Mwakagile, D., et al., *High frequency of sexually transmitted diseases among pregnant women in Dar es Salaam, Tanzania: need for intervention*. East Afr Med J, 1996. **73**(10): p. 675-8.
20. Kwesigabo, G., et al., *Decline in the prevalence of HIV-1 infection in young women in the Kagera region of Tanzania*. J Acquir Immune Defic Syndr Hum Retrovirol, 1998. **17**(3): p. 262-8.
21. Kapiga, S.H., et al., *The incidence of HIV infection among women using family planning methods in Dar es Salaam, Tanzania*. AIDS, 1998. **12**(1): p. 75-84.



22. Kwesigabo, G., et al., *Prevalence of HIV infection among hospital patients in north west Tanzania*. *AIDS Care*, 1999. **11**(1): p. 87-93.
23. Kilewo, C., et al., *HIV counseling and testing of pregnant women in sub-Saharan Africa: experiences from a study on prevention of mother-to-child HIV-1 transmission in Dar es Salaam, Tanzania*. *J Acquir Immune Defic Syndr*, 2001. **28**(5): p. 458-62.
24. Kapiga, S.H., et al., *HIV-1 epidemic among female bar and hotel workers in northern Tanzania: risk factors and opportunities for prevention*. *J Acquir Immune Defic Syndr*, 2002. **29**(4): p. 409-17.
25. Kwesigabo, G., et al., *HIV-1 infection prevalence and incidence trends in areas of contrasting levels of infection in the Kagera region, Tanzania, 1987-2000*. *J Acquir Immune Defic Syndr*, 2005. **40**(5): p. 585-91.
26. Kwesigabo, G., et al., *Monitoring of HIV-1 infection prevalence and trends in the general population using pregnant women as a sentinel population: 9 years experience from the Kagera region of Tanzania*. *J Acquir Immune Defic Syndr*, 2000. **23**(5): p. 410-7.
27. Haukenes, G., et al., *The AIDS epidemic in Tanzania: rate of spread of HIV in blood donors and pregnant women in Dar es Salaam*. *Scand J Infect Dis*, 1992. **24**(6): p. 701-6.
28. Kilewo, C., et al., *Prevention of mother-to-child transmission of HIV-1 through breast-feeding by treating infants prophylactically with lamivudine in Dar es Salaam, Tanzania: the Mitra Study*. *J Acquir Immune Defic Syndr*, 2008. **48**(3): p. 315-23.
29. Kilewo, C., et al., *Prevention of mother-to-child transmission of HIV-1 through breastfeeding by treating mothers with triple antiretroviral therapy in Dar es Salaam, Tanzania: the Mitra Plus study*. *J Acquir Immune Defic Syndr*, 2009. **52**(3): p. 406-16.
30. Swai, R.O., et al., *Surveillance of HIV and syphilis infections among antenatal clinic attendees in Tanzania-2003/2004*. *BMC Public Health*, 2006. **6**: p. 91.
31. Matee, M.I., et al., *Prevalence of transfusion-associated viral infections and syphilis among blood donors in Muhimbili Medical Centre, Dar es Salaam, Tanzania*. *East Afr Med J*, 1999. **76**(3): p. 167-71.
32. Matee, M.I., P.M. Magesa, and E.F. Lyamuya, *Seroprevalence of human immunodeficiency virus, hepatitis B and C viruses and syphilis infections among blood donors at the Muhimbili National Hospital in Dar es Salaam, Tanzania*. *BMC Public Health*, 2006. **6**: p. 21.
33. Ministry of Health and Social Welfare, T.M., *National AIDS Control Programme HIV/AIDS/STI Surveillance Report No. 21, July 2009*.
34. Sharp, P.M., G.M. Shaw, and B.H. Hahn, *Simian immunodeficiency virus infection of chimpanzees*. *J Virol*, 2005. **79**(7): p. 3891-902.
35. Chen, Z., et al., *Genetic characterization of new West African simian immunodeficiency virus SIVsm: geographic clustering of household-derived SIV strains with human immunodeficiency virus type 2 subtypes and genetically diverse viruses from a single feral sooty mangabey troop*. *J Virol*, 1996. **70**(6): p. 3617-27.
36. Rubbert A, B.G., et al, *Pathogenesis of HIV-1 infection*. *HIV Medicine 2007*. Hoffman C, Rockstroh JK and KBS. 2007, Hamburg, Bonn, Paris: Flying publisher. 15th edition: 33-39.
37. Levy, J.A., *HIV pathogenesis: 25 years of progress and persistent challenges*. *AIDS*, 2009. **23**(2): p. 147-60.
38. Liu, R., et al., *Homozygous defect in HIV-1 coreceptor accounts for resistance of some multiply-exposed individuals to HIV-1 infection*. *Cell*, 1996. **86**(3): p. 367-77.
39. Preston, B.D., B.J. Poiesz, and L.A. Loeb, *Fidelity of HIV-1 reverse transcriptase*. *Science*, 1988. **242**(4882): p. 1168-71.
40. Roberts, J.D., K. Bebenek, and T.A. Kunkel, *The accuracy of reverse transcriptase from HIV-1*. *Science*, 1988. **242**(4882): p. 1171-3.
41. Takeuchi, Y., T. Nagumo, and H. Hoshino, *Low fidelity of cell-free DNA synthesis by reverse transcriptase of human immunodeficiency virus*. *J Virol*, 1988. **62**(10): p. 3900-2.

42. Coffin, J.M., *HIV population dynamics in vivo: implications for genetic variation, pathogenesis, and therapy*. Science, 1995. **267**(5197): p. 483-9.
43. Harris, R.S. and M.T. Liddament, *Retroviral restriction by APOBEC proteins*. Nat Rev Immunol, 2004. **4**(11): p. 868-77.
44. Takebe, Y., R. Uenishi, and X. Li, *Global molecular epidemiology of HIV: understanding the genesis of AIDS pandemic*. Adv Pharmacol, 2008. **56**: p. 1-25.
45. Reeves, J.D., et al., *Primary human immunodeficiency virus type 2 (HIV-2) isolates infect CD4-negative cells via CCR5 and CXCR4: comparison with HIV-1 and simian immunodeficiency virus and relevance to cell tropism in vivo*. J Virol, 1999. **73**(9): p. 7795-804.
46. Peeters, M., C. Toure-Kane, and J.N. Nkengasong, *Genetic diversity of HIV in Africa: impact on diagnosis, treatment, vaccine development and trials*. AIDS, 2003. **17**(18): p. 2547-60.
47. Robertson, D.L., et al., *HIV-1 nomenclature proposal*. Science, 2000. **288**(5463): p. 55-6.
48. Binley, J.M., et al., *Comprehensive cross-clade neutralization analysis of a panel of anti-human immunodeficiency virus type 1 monoclonal antibodies*. J Virol, 2004. **78**(23): p. 13232-52.
49. Potts, K.E., et al., *Genetic heterogeneity of the V3 region of the HIV-1 envelope glycoprotein in Brazil. Brazilian Collaborative AIDS Research Group*. AIDS, 1993. **7**(9): p. 1191-7.
50. Lyamuya, E., et al., *Evaluation of a prototype Amplicor PCR assay for detection of human immunodeficiency virus type 1 DNA in blood samples from Tanzanian adults infected with HIV-1 subtypes A, C and D*. J Clin Virol, 2000. **17**(1): p. 57-63.
51. Kiwelu, I.E., et al., *HIV type 1 subtypes among bar and hotel workers in Moshi, Tanzania*. AIDS Res Hum Retroviruses, 2003. **19**(1): p. 57-64.
52. Arroyo, M.A., et al., *HIV type 1 subtypes among blood donors in the Mbeya region of southwest Tanzania*. AIDS Res Hum Retroviruses, 2004. **20**(8): p. 895-901.
53. Nyombi, B.M., et al., *Diversity of human immunodeficiency virus type 1 subtypes in Kagera and Kilimanjaro regions, Tanzania*. AIDS Res Hum Retroviruses, 2008. **24**(6): p. 761-9.
54. Mosha, F., et al., *Prevalence of Genotypic Resistance to Antiretroviral Drugs in Treatment-Naive Youths Infected with Diverse HIV Type 1 Subtypes and Recombinant Forms in Dar es Salaam, Tanzania*. AIDS Res Hum Retroviruses, 2011. **27**(4): p. 377-82.
55. Bobkov, A., et al., *Identification of an env G subtype and heterogeneity of HIV-1 strains in the Russian Federation and Belarus*. AIDS, 1994. **8**(12): p. 1649-55.
56. Laukkanen, T., et al., *Virtually full-length sequences of HIV type 1 subtype J reference strains*. AIDS Res Hum Retroviruses, 1999. **15**(3): p. 293-7.
57. Roques, P., et al., *An unusual HIV type 1 env sequence embedded in a mosaic virus from Cameroon: identification of a new env clade. European Network on the study of in utero transmission of HIV-1*. AIDS Res Hum Retroviruses, 1999. **15**(17): p. 1585-9.
58. Nelson, K.E., et al., *Survival of blood donors and their spouses with HIV-1 subtype E (CRF01\_A\_E) infection in northern Thailand, 1992-2007*. AIDS, 2007. **21 Suppl 6**: p. S47-54.
59. Konings, F.A., et al., *Human immunodeficiency virus type 1 (HIV-1) circulating recombinant form 02\_AG (CRF02\_AG) has a higher in vitro replicative capacity than its parental subtypes A and G*. J Med Virol, 2006. **78**(5): p. 523-34.
60. Peeters, M., et al., *Geographical distribution of HIV-1 group O viruses in Africa*. AIDS, 1997. **11**(4): p. 493-8.
61. Simon, F., et al., *Identification of a new human immunodeficiency virus type 1 distinct from group M and group O*. Nat Med, 1998. **4**(9): p. 1032-7.
62. Taylor, B.S., et al., *The challenge of HIV-1 subtype diversity*. N Engl J Med, 2008. **358**(15): p. 1590-602.

63. Masur, H., et al., *An outbreak of community-acquired Pneumocystis carinii pneumonia: initial manifestation of cellular immune dysfunction*. N Engl J Med, 1981. **305**(24): p. 1431-8.
64. Mildvan, D., et al., *Opportunistic infections and immune deficiency in homosexual men*. Ann Intern Med, 1982. **96**(6 Pt 1): p. 700-4.
65. Siegal, F.P., et al., *Severe acquired immunodeficiency in male homosexuals, manifested by chronic perianal ulcerative herpes simplex lesions*. N Engl J Med, 1981. **305**(24): p. 1439-44.
66. Wodak, A. and J. Gold, *HIV antibodies in intravenous drug abusers*. Med J Aust, 1986. **145**(6): p. 298.
67. Williams, A.B., R.T. D'Aquila, and A.E. Williams, *HIV infection in intravenous drug abusers*. Image J Nurs Sch, 1987. **19**(4): p. 179-83.
68. Harris, C., et al., *Immunodeficiency in female sexual partners of men with the acquired immunodeficiency syndrome*. N Engl J Med, 1983. **308**(20): p. 1181-4.
69. Quinn, T.C., *Global burden of the HIV pandemic*. Lancet, 1996. **348**(9020): p. 99-106.
70. De Cock, K.M., et al., *Prevention of mother-to-child HIV transmission in resource-poor countries: translating research into policy and practice*. JAMA, 2000. **283**(9): p. 1175-82.
71. Edgeworth, R.L. and K.E. Ugen, *Immunopathological factors for vertical transmission of HIV-1*. Pathobiology, 2000. **68**(2): p. 53-67.
72. Lallemand, M., et al., *A trial of shortened zidovudine regimens to prevent mother-to-child transmission of human immunodeficiency virus type 1*. Perinatal HIV Prevention Trial (Thailand) Investigators. N Engl J Med, 2000. **343**(14): p. 982-91.
73. Karlsson, K., et al., *Late postnatal transmission of human immunodeficiency virus type 1 infection from mothers to infants in Dar es Salaam, Tanzania*. Pediatr Infect Dis J, 1997. **16**(10): p. 963-7.
74. Dabis, F. and E.R. Ekpini, *HIV-1/AIDS and maternal and child health in Africa*. Lancet, 2002. **359**(9323): p. 2097-104.
75. Leigh, J.P., et al., *Costs of needlestick injuries and subsequent hepatitis and HIV infection*. Curr Med Res Opin, 2007. **23**(9): p. 2093-105.
76. UNAIDS/WHO, *AIDS epidemic update*. 2002.
77. Quinn, T.C., et al., *Viral load and heterosexual transmission of human immunodeficiency virus type 1*. Rakai Project Study Group. N Engl J Med, 2000. **342**(13): p. 921-9.
78. Plummer, F.A., et al., *Cofactors in male-female sexual transmission of human immunodeficiency virus type 1*. J Infect Dis, 1991. **163**(2): p. 233-9.
79. Lamptey, P.R., *Reducing heterosexual transmission of HIV in poor countries*. BMJ, 2002. **324**(7331): p. 207-11.
80. Bagasra, O., et al., *Detection of human immunodeficiency virus type 1 provirus in mononuclear cells by in situ polymerase chain reaction*. N Engl J Med, 1992. **326**(21): p. 1385-91.
81. Bagasra, O., et al., *High percentages of CD4-positive lymphocytes harbor the HIV-1 provirus in the blood of certain infected individuals*. AIDS, 1993. **7**(11): p. 1419-25.
82. Hsia, K. and S.A. Spector, *Human immunodeficiency virus DNA is present in a high percentage of CD4+ lymphocytes of seropositive individuals*. J Infect Dis, 1991. **164**(3): p. 470-5.
83. Levy, J.A., *The transmission of HIV and factors influencing progression to AIDS*. Am J Med, 1993. **95**(1): p. 86-100.
84. Schnittman, S.M., et al., *Increasing viral burden in CD4+ T cells from patients with human immunodeficiency virus (HIV) infection reflects rapidly progressive immunosuppression and clinical disease*. Ann Intern Med, 1990. **113**(6): p. 438-43.
85. Levy, J.A., *HIV research: a need to focus on the right target*. Lancet, 1995. **345**(8965): p. 1619-21.
86. Anderson, D.J., et al., *Effects of disease stage and zidovudine therapy on the detection of human immunodeficiency virus type 1 in semen*. JAMA, 1992. **267**(20): p. 2769-74.

87. Ho, D.D., et al., *HTLV-III in the semen and blood of a healthy homosexual man*. Science, 1984. **226**(4673): p. 451-3.
88. Levy, J.A., *The transmission of AIDS: the case of the infected cell*. JAMA, 1988. **259**(20): p. 3037-8.
89. Mermin, J.H., et al., *Detection of human immunodeficiency virus DNA and RNA in semen by the polymerase chain reaction*. J Infect Dis, 1991. **164**(4): p. 769-72.
90. Vogt, M.W., et al., *Isolation of HTLV-III/LAV from cervical secretions of women at risk for AIDS*. Lancet, 1986. **1**(8480): p. 525-7.
91. Wofsy, C.B., et al., *Isolation of AIDS-associated retrovirus from genital secretions of women with antibodies to the virus*. Lancet, 1986. **1**(8480): p. 527-9.
92. Zagury, D., et al., *HTLV-III in cells cultured from semen of two patients with AIDS*. Science, 1984. **226**(4673): p. 449-51.
93. John-Stewart, G.C., et al., *Subtype C Is associated with increased vaginal shedding of HIV-1*. J Infect Dis, 2005. **192**(3): p. 492-6.
94. Renjifo, B., et al., *Preferential in-utero transmission of HIV-1 subtype C as compared to HIV-1 subtype A or D*. AIDS, 2004. **18**(12): p. 1629-36.
95. Rousseau, C.M., et al., *Longitudinal analysis of human immunodeficiency virus type 1 RNA in breast milk and of its relationship to infant infection and maternal disease*. J Infect Dis, 2003. **187**(5): p. 741-7.
96. Semba, R.D., et al., *Human immunodeficiency virus load in breast milk, mastitis, and mother-to-child transmission of human immunodeficiency virus type 1*. J Infect Dis, 1999. **180**(1): p. 93-8.
97. Mellors, J.W., et al., *Plasma viral load and CD4+ lymphocytes as prognostic markers of HIV-1 infection*. Ann Intern Med, 1997. **126**(12): p. 946-54.
98. Douek, D.C., M. Roederer, and R.A. Koup, *Emerging concepts in the immunopathogenesis of AIDS*. Annu Rev Med, 2009. **60**: p. 471-84.
99. Giorgi, J.V., et al., *Shorter survival in advanced human immunodeficiency virus type 1 infection is more closely associated with T lymphocyte activation than with plasma virus burden or virus chemokine coreceptor usage*. J Infect Dis, 1999. **179**(4): p. 859-70.
100. Eller, M.A., et al., *Innate and adaptive immune responses both contribute to pathological CD4 T cell activation in HIV-1 infected Ugandans*. PLoS One, 2011. **6**(4): p. e18779.
101. Cohen, M.S., et al., *Acute HIV-1 Infection*. N Engl J Med, 2011. **364**(20): p. 1943-54.
102. Haase, A.T., *Early events in sexual transmission of HIV and SIV and opportunities for interventions*. Annu Rev Med, 2011. **62**: p. 127-39.
103. Kader, M., et al., *CD4 T cell subsets in the mucosa are CD28+Ki-67-HLA-DR-CD69+ but show differential infection based on alpha4beta7 receptor expression during acute SIV infection*. J Med Primatol, 2009. **38 Suppl 1**: p. 24-31.
104. Brenchley, J.M., et al., *Microbial translocation is a cause of systemic immune activation in chronic HIV infection*. Nat Med, 2006. **12**(12): p. 1365-71.
105. Koup, R.A., et al., *Temporal association of cellular immune responses with the initial control of viremia in primary human immunodeficiency virus type 1 syndrome*. J Virol, 1994. **68**(7): p. 4650-5.
106. Borrow, P., et al., *Virus-specific CD8+ cytotoxic T-lymphocyte activity associated with control of viremia in primary human immunodeficiency virus type 1 infection*. J Virol, 1994. **68**(9): p. 6103-10.
107. Shearer, G.M. and M. Clerici, *Early T-helper cell defects in HIV infection*. AIDS, 1991. **5**(3): p. 245-53.
108. Jaffar, S., et al., *The natural history of HIV-1 and HIV-2 infections in adults in Africa: a literature review*. Bull World Health Organ, 2004. **82**(6): p. 462-9.
109. Chakraborty, R., *HIV-1 infection in children: a clinical and immunologic overview*. Curr HIV Res, 2005. **3**(1): p. 31-41.
110. Rutherford, G.W., et al., *Course of HIV-1 infection in a cohort of homosexual and bisexual men: an 11 year follow up study*. BMJ, 1990. **301**(6762): p. 1183-8.

111. Veugelers, P.J., et al., *Incidence and prognostic significance of symptomatic primary human immunodeficiency virus type 1 infection in homosexual men.* J Infect Dis, 1997. **176**(1): p. 112-7.
112. Vergis, E.N. and J.W. Mellors, *Natural history of HIV-1 infection.* Infect Dis Clin North Am, 2000. **14**(4): p. 809-25, v-vi.
113. Anzala, O.A., et al., *Rapid progression to disease in African sex workers with human immunodeficiency virus type 1 infection.* J Infect Dis, 1995. **171**(3): p. 686-9.
114. Leroy, V., et al., *Four years of natural history of HIV-1 infection in african women: a prospective cohort study in Kigali (Rwanda), 1988-1993.* J Acquir Immune Defic Syndr Hum Retroviro, 1995. **9**(4): p. 415-21.
115. Jaffar, S. and A.J. Hall, *Disease progression in HIV-1 or HIV-2-infected individuals of West African origin resident in the West.* AIDS, 1997. **11**(11): p. 1398-9.
116. Morgan, D., et al., *Progression to symptomatic disease in people infected with HIV-1 in rural Uganda: prospective cohort study.* BMJ, 2002. **324**(7331): p. 193-6.
117. Salamon, R., et al., *Clinical and biological evolution of HIV-1 seroconverters in Abidjan, Cote d'Ivoire, 1997-2000.* J Acquir Immune Defic Syndr, 2002. **29**(2): p. 149-57.
118. Bakari, M., et al., *The natural course of disease following HIV-1 infection in dar es salaam, Tanzania: a study among hotel workers relating clinical events to CD4 T-lymphocyte counts.* Scand J Infect Dis, 2004. **36**(6-7): p. 466-73.
119. Urassa, W., et al., *Rate of decline of absolute number and percentage of CD4 T lymphocytes among HIV-1-infected adults in Dar es Salaam, Tanzania.* AIDS, 2004. **18**(3): p. 433-8.
120. Campbell-Yesufu, O.T. and R.T. Gandhi, *Update on human immunodeficiency virus (HIV)-2 infection.* Clin Infect Dis, 2011. **52**(6): p. 780-7.
121. Murray, J.F., *Pulmonary complications of HIV-1 infection among adults living in Sub-Saharan Africa.* Int J Tuberc Lung Dis, 2005. **9**(8): p. 826-35.
122. Onen, C., *Clinical diagnosis of AIDS and HIV-related diseases. AIDS in Africa.* Second edition ed, ed. M.S. M Essex, Kanki PJ, Marlink RG and T DS. 2002, New York, USA: Kluwer Academic Plenum/Publishers. 297-321.
123. Cheung, M.C., L. Pantanowitz, and B.J. Dezube, *AIDS-related malignancies: emerging challenges in the era of highly active antiretroviral therapy.* Oncologist, 2005. **10**(6): p. 412-26.
124. Lim, S.T. and A.M. Levine, *Recent advances in acquired immunodeficiency syndrome (AIDS)-related lymphoma.* CA Cancer J Clin, 2005. **55**(4): p. 229-41; 260-1, 264.
125. Kanki, P.J., et al., *Human immunodeficiency virus type 1 subtypes differ in disease progression.* J Infect Dis, 1999. **179**(1): p. 68-73.
126. Kaleebu, P., et al., *Effect of human immunodeficiency virus (HIV) type 1 envelope subtypes A and D on disease progression in a large cohort of HIV-1-positive persons in Uganda.* J Infect Dis, 2002. **185**(9): p. 1244-50.
127. Kiwanuka, N., et al., *Effect of human immunodeficiency virus Type 1 (HIV-1) subtype on disease progression in persons from Rakai, Uganda, with incident HIV-1 infection.* J Infect Dis, 2008. **197**(5): p. 707-13.
128. Vasan, A., et al., *Different rates of disease progression of HIV type 1 infection in Tanzania based on infecting subtype.* Clin Infect Dis, 2006. **42**(6): p. 843-52.
129. Levy, J.A., I. Scott, and C. Mackewicz, *Protection from HIV/AIDS: the importance of innate immunity.* Clin Immunol, 2003. **108**(3): p. 167-74.
130. Mogensen, T.H., et al., *Innate immune recognition and activation during HIV infection.* Retrovirology, 2010. **7**: p. 54.
131. Lehner, T., et al., *The emerging role of innate immunity in protection against HIV-1 infection.* Vaccine, 2008. **26**(24): p. 2997-3001.
132. Biron, C.A., et al., *Natural killer cells in antiviral defense: function and regulation by innate cytokines.* Annu Rev Immunol, 1999. **17**: p. 189-220.
133. Spear, G.T., et al., *Neutralization of human immunodeficiency virus type 1 by complement occurs by viral lysis.* J Virol, 1990. **64**(12): p. 5869-73.

134. Spear, G.T., et al., *Complement activation by human monoclonal antibodies to human immunodeficiency virus*. J Virol, 1993. **67**(1): p. 53-9.
135. Solder, B.M., et al., *HIV and HIV-infected cells differentially activate the human complement system independent of antibody*. Immunol Lett, 1989. **22**(2): p. 135-45.
136. Susal, C., et al., *Complement activation by recombinant HIV-1 glycoprotein gp120*. J Immunol, 1994. **152**(12): p. 6028-34.
137. Jakubik, J.J., et al., *Immune complexes containing human immunodeficiency virus type 1 primary isolates bind to lymphoid tissue B lymphocytes and are infectious for T lymphocytes*. J Virol, 2000. **74**(1): p. 552-5.
138. Olinger, G.G., M. Saifuddin, and G.T. Spear, *CD4-Negative cells bind human immunodeficiency virus type 1 and efficiently transfer virus to T cells*. J Virol, 2000. **74**(18): p. 8550-7.
139. Tomescu, C., S. Abdulhaqq, and L.J. Montaner, *Evidence for the innate immune response as a correlate of protection in human immunodeficiency virus (HIV)-1 highly exposed seronegative subjects (HESN)*. Clin Exp Immunol, 2011. **164**(2): p. 158-69.
140. Soghoian, D.Z. and H. Streeck, *Cytolytic CD4(+) T cells in viral immunity*. Expert Rev Vaccines, 2010. **9**(12): p. 1453-63.
141. Rosenberg, E.S., et al., *Vigorous HIV-1-specific CD4+ T cell responses associated with control of viremia*. Science, 1997. **278**(5342): p. 1447-50.
142. Sandberg, J.K., N.M. Fast, and D.F. Nixon, *Functional heterogeneity of cytokines and cytolytic effector molecules in human CD8+ T lymphocytes*. J Immunol, 2001. **167**(1): p. 181-7.
143. Voskoboinik, I., M.J. Smyth, and J.A. Trapani, *Perforin-mediated target-cell death and immune homeostasis*. Nat Rev Immunol, 2006. **6**(12): p. 940-52.
144. Trapani, J.A. and M.J. Smyth, *Functional significance of the perforin/granzyme cell death pathway*. Nat Rev Immunol, 2002. **2**(10): p. 735-47.
145. Bollinger, R.C., et al., *Cellular immune responses to HIV-1 in progressive and non-progressive infections*. AIDS, 1996. **10 Suppl A**: p. S85-96.
146. Schmitz, J.E., et al., *Control of viremia in simian immunodeficiency virus infection by CD8+ lymphocytes*. Science, 1999. **283**(5403): p. 857-60.
147. Jin, X., et al., *Dramatic rise in plasma viremia after CD8(+) T cell depletion in simian immunodeficiency virus-infected macaques*. J Exp Med, 1999. **189**(6): p. 991-8.
148. Kiepiela, P., et al., *CD8+ T-cell responses to different HIV proteins have discordant associations with viral load*. Nat Med, 2007. **13**(1): p. 46-53.
149. Geldmacher, C., et al., *CD8 T-cell recognition of multiple epitopes within specific Gag regions is associated with maintenance of a low steady-state viremia in human immunodeficiency virus type 1-seropositive patients*. J Virol, 2007. **81**(5): p. 2440-8.
150. Rowland-Jones, S.L. and A. McMichael, *Immune responses in HIV-exposed seronegatives: have they repelled the virus?* Curr Opin Immunol, 1995. **7**(4): p. 448-55.
151. Hirbod, T. and K. Broliden, *Mucosal immune responses in the genital tract of HIV-1-exposed uninfected women*. J Intern Med, 2007. **262**(1): p. 44-58.
152. Hirbod, T., et al., *HIV-neutralizing immunoglobulin A and HIV-specific proliferation are independently associated with reduced HIV acquisition in Kenyan sex workers*. AIDS, 2008. **22**(6): p. 727-35.
153. Buchbinder, S.P., et al., *Long-term HIV-1 infection without immunologic progression*. AIDS, 1994. **8**(8): p. 1123-8.
154. Deeks, S.G. and B.D. Walker, *Human immunodeficiency virus controllers: mechanisms of durable virus control in the absence of antiretroviral therapy*. Immunity, 2007. **27**(3): p. 406-16.
155. Migueles, S.A., et al., *Lytic granule loading of CD8+ T cells is required for HIV-infected cell elimination associated with immune control*. Immunity, 2008. **29**(6): p. 1009-21.
156. Betts, M.R., et al., *HIV nonprogressors preferentially maintain highly functional HIV-specific CD8+ T cells*. Blood, 2006. **107**(12): p. 4781-9.

157. Broliden, P.A., et al., *Identification of human neutralization-inducing regions of the human immunodeficiency virus type 1 envelope glycoproteins*. Proc Natl Acad Sci U S A, 1992. **89**(2): p. 461-5.
158. Srivastava, I.K., J.B. Ulmer, and S.W. Barnett, *Neutralizing antibody responses to HIV: role in protective immunity and challenges for vaccine design*. Expert Rev Vaccines, 2004. **3**(4 Suppl): p. S33-52.
159. McElrath, M.J. and B.F. Haynes, *Induction of immunity to human immunodeficiency virus type-1 by vaccination*. Immunity, 2010. **33**(4): p. 542-54.
160. Mascola, J.R. and D.C. Montefiori, *The role of antibodies in HIV vaccines*. Annu Rev Immunol, 2010. **28**: p. 413-44.
161. Walker, L.M., et al., *Broad and potent neutralizing antibodies from an African donor reveal a new HIV-1 vaccine target*. Science, 2009. **326**(5950): p. 285-9.
162. Evans, L.A., et al., *Antibody-dependent cellular cytotoxicity is directed against both the gp120 and gp41 envelope proteins of HIV*. AIDS, 1989. **3**(5): p. 273-6.
163. Ljunggren, K., et al., *Antibody-dependent cellular cytotoxicity detects type- and strain-specific antigens among human immunodeficiency virus types 1 and 2 and simian immunodeficiency virus SIVmac isolates*. J Virol, 1989. **63**(8): p. 3376-81.
164. Ljunggren, K., et al., *IgG subclass response to HIV in relation to antibody-dependent cellular cytotoxicity at different clinical stages*. Clin Exp Immunol, 1988. **73**(3): p. 343-7.
165. Norley, S.G., et al., *Demonstration of cross-reactive antibodies able to elicit lysis of both HIV-1- and HIV-2-infected cells*. J Immunol, 1990. **145**(6): p. 1700-5.
166. Rook, A.H., et al., *Sera from HTLV-III/LAV antibody-positive individuals mediate antibody-dependent cellular cytotoxicity against HTLV-III/LAV-infected T cells*. J Immunol, 1987. **138**(4): p. 1064-7.
167. Baum, L.L., et al., *HIV-1 gp120-specific antibody-dependent cell-mediated cytotoxicity correlates with rate of disease progression*. J Immunol, 1996. **157**(5): p. 2168-73.
168. Lambotte, O., et al., *Heterogeneous neutralizing antibody and antibody-dependent cell cytotoxicity responses in HIV-1 elite controllers*. AIDS, 2009. **23**(8): p. 897-906.
169. Gomez-Roman, V.R., et al., *Vaccine-elicited antibodies mediate antibody-dependent cellular cytotoxicity correlated with significantly reduced acute viremia in rhesus macaques challenged with SIVmac251*. J Immunol, 2005. **174**(4): p. 2185-9.
170. Fanales-Belasio, E., et al., *HIV virology and pathogenetic mechanisms of infection: a brief overview*. Ann Ist Super Sanita, 2010. **46**(1): p. 5-14.
171. Weber, B., *Screening of HIV infection: role of molecular and immunological assays*. Expert Rev Mol Diagn, 2006. **6**(3): p. 399-411.
172. WHO/UNAIDS, *Joint United Nations Programme on HIV/AIDS (UNAIDS)-WHO. Revised recommendations for the selection and use of HIV antibody tests*. Wkly Epidemiol Rec, 1997. **72**(12): p. 81-7.
173. *Global programme on AIDS. Recommendations for the selection and use of HIV antibody tests*. Wkly Epidemiol Rec, 1992. **67**(20): p. 145-9.
174. Brust, S., et al., *Shortening of the diagnostic window with a new combined HIV p24 antigen and anti-HIV-1/2/O screening test*. J Virol Methods, 2000. **90**(2): p. 153-65.
175. Ly, T.D., S. Laperche, and A.M. Courouce, *Early detection of human immunodeficiency virus infection using third- and fourth-generation screening assays*. Eur J Clin Microbiol Infect Dis, 2001. **20**(2): p. 104-10.
176. Ly, T.D., et al., *Seven human immunodeficiency virus (HIV) antigen-antibody combination assays: evaluation of HIV seroconversion sensitivity and subtype detection*. J Clin Microbiol, 2001. **39**(9): p. 3122-8.
177. Saville, R.D., et al., *Fourth-generation enzyme-linked immunosorbent assay for the simultaneous detection of human immunodeficiency virus antigen and antibody*. J Clin Microbiol, 2001. **39**(7): p. 2518-24.

178. Giles, R.E., K.R. Perry, and J.V. Parry, *Simple/rapid test devices for anti-HIV screening: do they come up to the mark?* J Med Virol, 1999. **59**(1): p. 104-9.
179. Ekwueme, D.U., et al., *Cost comparison of three HIV counseling and testing technologies.* Am J Prev Med, 2003. **25**(2): p. 112-21.
180. Gray, R.H., et al., *Limitations of rapid HIV-1 tests during screening for trials in Uganda: diagnostic test accuracy study.* BMJ, 2007. **335**(7612): p. 188.
181. Anzala, O., et al., *Sensitivity and specificity of HIV rapid tests used for research and voluntary counselling and testing.* East Afr Med J, 2008. **85**(10): p. 500-4.
182. Black, V., et al., *Poor sensitivity of field rapid HIV testing: implications for mother-to-child transmission programme.* BJOG, 2009. **116**(13): p. 1805-8.
183. Granade, T.C., *Use of rapid HIV antibody testing for controlling the HIV pandemic.* Expert Rev Anti Infect Ther, 2005. **3**(6): p. 957-69.
184. The consortium for Retrovirus Serology Standardization, *Serological diagnosis of human immunodeficiency virus infection by Western blot testing.* JAMA, 1988. **260**(5): p. 674-9.
185. CDC, *Interpretive criteria used to report western blot results for HIV-1-antibody testing--United States.* MMWR Morb Mortal Wkly Rep, 1991. **40**(40): p. 692-5.
186. Tebourski, F., A. Slim, and A. Elgaaied, *The significance of combining World Health Organization and Center for Disease Control criteria to resolve indeterminate human immunodeficiency virus type-1 Western blot results.* Diagn Microbiol Infect Dis, 2004. **48**(1): p. 59-61.
187. Urassa, W.K., et al., *Alternative confirmatory strategies in HIV-1 antibody testing.* J Acquir Immune Defic Syndr, 1992. **5**(2): p. 170-6.
188. Urassa, W., et al., *Evaluation of the WHO human immunodeficiency virus (HIV) antibody testing strategy for the diagnosis of HIV infection.* Clin Diagn Virol, 1994. **2**(1): p. 1-6.
189. Urassa, W., et al., *The accuracy of an alternative confirmatory strategy for detection of antibodies to HIV-1: experience from a regional laboratory in Kagera, Tanzania.* J Clin Virol, 1999. **14**(1): p. 25-9.
190. Nunn, A.J., et al., *Algorithms for detecting antibodies to HIV-1: results from a rural Ugandan cohort.* AIDS, 1993. **7**(8): p. 1057-61.
191. Carvalho, M.B., et al., *Risk factor analysis and serological diagnosis of HIV-1/HIV-2 infection in a Brazilian blood donor population: validation of the World Health Organization strategy for HIV testing.* AIDS, 1996. **10**(10): p. 1135-40.
192. Andersson, S., et al., *Field evaluation of alternative testing strategies for diagnosis and differentiation of HIV-1 and HIV-2 infections in an HIV-1 and HIV-2-prevalent area.* AIDS, 1997. **11**(15): p. 1815-22.
193. Meda, N., et al., *Serological diagnosis of human immuno-deficiency virus in Burkina Faso: reliable, practical strategies using less expensive commercial test kits.* Bull World Health Organ, 1999. **77**(9): p. 731-9.
194. Nkengasong, J.N., et al., *Evaluation of HIV serial and parallel serologic testing algorithms in Abidjan, Cote d'Ivoire.* AIDS, 1999. **13**(1): p. 109-17.
195. Stetler, H.C., et al., *Field evaluation of rapid HIV serologic tests for screening and confirming HIV-1 infection in Honduras.* AIDS, 1997. **11**(3): p. 369-75.
196. McKenna, S.L., et al., *Rapid HIV testing and counseling for voluntary testing centers in Africa.* AIDS, 1997. **11 Suppl 1**: p. S103-10.
197. Constantine, N.T., et al., *Diagnostic challenges for rapid human immunodeficiency virus assays. Performance using HIV-1 group O, HIV-1 group M, and HIV-2 samples.* J Hum Virol, 1997. **1**(1): p. 45-51.
198. Urassa, W., et al., *Evaluation of an alternative confirmatory strategy for the diagnosis of HIV infection in Dar Es Salaam, Tanzania, based on simple rapid assays.* J Virol Methods, 2002. **100**(1-2): p. 115-20.
199. Ferreira Junior, O.C., et al., *Evaluation of rapid tests for anti-HIV detection in Brazil.* AIDS, 2005. **19 Suppl 4**: p. S70-5.
200. Vijayakumar, T.S., et al., *Performance of a rapid immunochromatographic screening test for detection of antibodies to human immunodeficiency virus type 1 (HIV-1) and HIV-2: experience at a tertiary care hospital in South India.* J Clin Microbiol, 2005. **43**(8): p. 4194-6.



201. Menard, D., et al., *Evaluation of rapid HIV testing strategies in under equipped laboratories in the Central African Republic*. J Virol Methods, 2005. **126**(1-2): p. 75-80.
202. Eller, L.A., et al., *Large-scale human immunodeficiency virus rapid test evaluation in a low-prevalence ugandan blood bank population*. J Clin Microbiol, 2007. **45**(10): p. 3281-5.
203. Burgard, M., et al., *The use of viral culture and p24 antigen testing to diagnose human immunodeficiency virus infection in neonates. The HIV Infection in Newborns French Collaborative Study Group*. N Engl J Med, 1992. **327**(17): p. 1192-7.
204. Miles, S.A., et al., *Rapid serologic testing with immune-complex-dissociated HIV p24 antigen for early detection of HIV infection in neonates. Southern California Pediatric AIDS Consortium*. N Engl J Med, 1993. **328**(5): p. 297-302.
205. Schupbach, J., et al., *Sensitive detection and early prognostic significance of p24 antigen in heat-denatured plasma of human immunodeficiency virus type 1-infected infants. Swiss Neonatal HIV Study Group*. J Infect Dis, 1994. **170**(2): p. 318-24.
206. Nielsen, K., et al., *Immune complex-dissociated p24 antigenemia in the diagnosis of human immunodeficiency virus infection in vertically infected Brazilian children*. Pediatr Infect Dis J, 1995. **14**(1): p. 67-9.
207. Lyamuya, E., et al., *Performance of a modified HIV-1 p24 antigen assay for early diagnosis of HIV-1 infection in infants and prediction of mother-to-infant transmission of HIV-1 in Dar es Salaam, Tanzania*. J Acquir Immune Defic Syndr Hum Retrovirol, 1996. **12**(4): p. 421-6.
208. Paul, M.O., et al., *Diagnosis of human immunodeficiency virus type 1 infection in infants by immune complex dissociation p24 assay*. Clin Diagn Lab Immunol, 1997. **4**(1): p. 75-8.
209. Nadal, D., et al., *Prospective evaluation of amplification-boosted ELISA for heat-denatured p24 antigen for diagnosis and monitoring of pediatric human immunodeficiency virus type 1 infection*. J Infect Dis, 1999. **180**(4): p. 1089-95.
210. Guay, L.A., et al., *HIV-1 ICD p24 antigen detection in ugandan infants: use in early diagnosis of infection and as a marker of disease progression*. J Med Virol, 2000. **62**(4): p. 426-34.
211. Sutthent, R., et al., *p24 Antigen detection assay modified with a booster step for diagnosis and monitoring of human immunodeficiency virus type 1 infection*. J Clin Microbiol, 2003. **41**(3): p. 1016-22.
212. Sherman, G.G., G. Stevens, and W.S. Stevens, *Affordable diagnosis of human immunodeficiency virus infection in infants by p24 antigen detection*. Pediatr Infect Dis J, 2004. **23**(2): p. 173-6.
213. De Baets, A.J., et al., *Pediatric human immunodeficiency virus screening in an African district hospital*. Clin Diagn Lab Immunol, 2005. **12**(1): p. 86-92.
214. Patton, J.C., et al., *Ultrasensitive human immunodeficiency virus type 1 p24 antigen assay modified for use on dried whole-blood spots as a reliable, affordable test for infant diagnosis*. Clin Vaccine Immunol, 2006. **13**(1): p. 152-5.
215. Schupbach, J., *Measurement of HIV-1 p24 antigen by signal-amplification-boosted ELISA of heat-denatured plasma is a simple and inexpensive alternative to tests for viral RNA*. AIDS Rev, 2002. **4**(2): p. 83-92.
216. Respass, R.A., et al., *Evaluation of an ultrasensitive p24 antigen assay as a potential alternative to human immunodeficiency virus type 1 RNA viral load assay in resource-limited settings*. J Clin Microbiol, 2005. **43**(1): p. 506-8.
217. Parpia, Z.A., et al., *p24 antigen rapid test for diagnosis of acute pediatric HIV infection*. J Acquir Immune Defic Syndr, 2010. **55**(4): p. 413-9.
218. Branson, B.M., *State of the art for diagnosis of HIV infection*. Clin Infect Dis, 2007. **45 Suppl 4**: p. S221-5.
219. Read, J.S., *Diagnosis of HIV-1 infection in children younger than 18 months in the United States*. Pediatrics, 2007. **120**(6): p. e1547-62.

220. Raboud, J.M., et al., *Variation in plasma RNA levels, CD4 cell counts, and p24 antigen levels in clinically stable men with human immunodeficiency virus infection.* J Infect Dis, 1996. **174**(1): p. 191-4.
221. Fiebig, E.W., et al., *Dynamics of HIV viremia and antibody seroconversion in plasma donors: implications for diagnosis and staging of primary HIV infection.* AIDS, 2003. **17**(13): p. 1871-9.
222. Palmer, S., et al., *New real-time reverse transcriptase-initiated PCR assay with single-copy sensitivity for human immunodeficiency virus type 1 RNA in plasma.* J Clin Microbiol, 2003. **41**(10): p. 4531-6.
223. Ramratnam, B., et al., *Rapid production and clearance of HIV-1 and hepatitis C virus assessed by large volume plasma apheresis.* Lancet, 1999. **354**(9192): p. 1782-5.
224. Lambert, J.S., et al., *Performance characteristics of HIV-1 culture and HIV-1 DNA and RNA amplification assays for early diagnosis of perinatal HIV-1 infection.* J Acquir Immune Defic Syndr, 2003. **34**(5): p. 512-9.
225. Cunningham, C.K., et al., *Comparison of human immunodeficiency virus 1 DNA polymerase chain reaction and qualitative and quantitative RNA polymerase chain reaction in human immunodeficiency virus 1-exposed infants.* Pediatr Infect Dis J, 1999. **18**(1): p. 30-5.
226. Delamare, C., et al., *HIV-1 RNA detection in plasma for the diagnosis of infection in neonates. The French Pediatric HIV Infection Study Group.* J Acquir Immune Defic Syndr Hum Retrovirol, 1997. **15**(2): p. 121-5.
227. Steketee, R.W., et al., *Early detection of perinatal human immunodeficiency virus (HIV) type 1 infection using HIV RNA amplification and detection. New York City Perinatal HIV Transmission Collaborative Study.* J Infect Dis, 1997. **175**(3): p. 707-11.
228. Simonds, R.J., et al., *Sensitivity and specificity of a qualitative RNA detection assay to diagnose HIV infection in young infants. Perinatal AIDS Collaborative Transmission Study.* AIDS, 1998. **12**(12): p. 1545-9.
229. Young, N.L., et al., *Early diagnosis of HIV-1-infected infants in Thailand using RNA and DNA PCR assays sensitive to non-B subtypes.* J Acquir Immune Defic Syndr, 2000. **24**(5): p. 401-7.
230. Souza, I.E., et al., *RNA viral load test for early diagnosis of vertical transmission of HIV-1 infection.* J Acquir Immune Defic Syndr, 2000. **23**(4): p. 358-60.
231. Reisler, R.B., et al., *Early detection of reverse transcriptase activity in plasma of neonates infected with HIV-1: a comparative analysis with RNA-based and DNA-based testing using polymerase chain reaction.* J Acquir Immune Defic Syndr, 2001. **26**(1): p. 93-102.
232. Rouet, F., et al., *Early diagnosis of paediatric HIV-1 infection among African breast-fed children using a quantitative plasma HIV RNA assay.* AIDS, 2001. **15**(14): p. 1849-56.
233. Nesheim, S., et al., *Quantitative RNA testing for diagnosis of HIV-infected infants.* J Acquir Immune Defic Syndr, 2003. **32**(2): p. 192-5.
234. Rouet, F., et al., *Pediatric viral human immunodeficiency virus type 1 RNA levels, timing of infection, and disease progression in African HIV-1-infected children.* Pediatrics, 2003. **112**(4): p. e289.
235. Braun, J., et al., *A new quantitative HIV load assay based on plasma virion reverse transcriptase activity for the different types, groups and subtypes.* AIDS, 2003. **17**(3): p. 331-6.
236. Rouet, F., et al., *Transfer and evaluation of an automated, low-cost real-time reverse transcription-PCR test for diagnosis and monitoring of human immunodeficiency virus type 1 infection in a West African resource-limited setting.* J Clin Microbiol, 2005. **43**(6): p. 2709-17.
237. Sherman, G.G., et al., *Polymerase chain reaction for diagnosis of human immunodeficiency virus infection in infancy in low resource settings.* Pediatr Infect Dis J, 2005. **24**(11): p. 993-7.

238. Fischer, A., et al., *Simple DNA extraction method for dried blood spots and comparison of two PCR assays for diagnosis of vertical human immunodeficiency virus type 1 transmission in Rwanda*. J Clin Microbiol, 2004. **42**(1): p. 16-20.
239. Nyambi, P.N., et al., *Detection of human immunodeficiency virus type 1 (HIV-1) in heel prick blood on filter paper from children born to HIV-1-seropositive mothers*. J Clin Microbiol, 1994. **32**(11): p. 2858-60.
240. Sherman, G.G., et al., *Dried blood spots improve access to HIV diagnosis and care for infants in low-resource settings*. J Acquir Immune Defic Syndr, 2005. **38**(5): p. 615-7.
241. Beck, I.A., et al., *Simple, sensitive, and specific detection of human immunodeficiency virus type 1 subtype B DNA in dried blood samples for diagnosis in infants in the field*. J Clin Microbiol, 2001. **39**(1): p. 29-33.
242. Stevens, W., et al., *Role of the laboratory in ensuring global access to ARV treatment for HIV-infected children: consensus statement on the performance of laboratory assays for early infant diagnosis*. Open AIDS J, 2008. **2**: p. 17-25.
243. Krivine, A., et al., *A comparative study of virus isolation, polymerase chain reaction, and antigen detection in children of mothers infected with human immunodeficiency virus*. J Pediatr, 1990. **116**(3): p. 372-6.
244. De Rossi, A., et al., *Antigen detection, virus culture, polymerase chain reaction, and in vitro antibody production in the diagnosis of vertically transmitted HIV-1 infection*. AIDS, 1991. **5**(1): p. 15-20.
245. Kline, M.W., et al., *A comparative study of human immunodeficiency virus culture, polymerase chain reaction and anti-human immunodeficiency virus immunoglobulin A antibody detection in the diagnosis during early infancy of vertically acquired human immunodeficiency virus infection*. Pediatr Infect Dis J, 1994. **13**(2): p. 90-4.
246. Borkowsky, W., et al., *Early diagnosis of human immunodeficiency virus infection in children less than 6 months of age: comparison of polymerase chain reaction, culture, and plasma antigen capture techniques*. J Infect Dis, 1992. **166**(3): p. 616-9.
247. Hammer, S.M., et al., *Antiretroviral treatment of adult HIV infection: 2008 recommendations of the International AIDS Society-USA panel*. JAMA, 2008. **300**(5): p. 555-70.
248. Gilliam, B.L., D.J. Riedel, and R.R. Redfield, *Clinical use of CCR5 inhibitors in HIV and beyond*. J Transl Med, 2011. **9 Suppl 1**: p. S9.
249. Palella, F.J., Jr., et al., *Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. HIV Outpatient Study Investigators*. N Engl J Med, 1998. **338**(13): p. 853-60.
250. Hogg, R.S., et al., *Intermittent use of triple-combination therapy is predictive of mortality at baseline and after 1 year of follow-up*. AIDS, 2002. **16**(7): p. 1051-8.
251. Ministry of Health and Social Welfare, T., *National AIDS Control Programme HIV/AIDS Care and Treatment Plan 2003-2008: In National guidelines for the clinical management of HIV and AIDS, 2005*.
252. Mugusi, S.F., et al., *Effect of improved access to antiretroviral therapy on clinical characteristics of patients enrolled in the HIV care and treatment clinic, at Muhimbili National Hospital (MNH), Dar es Salaam, Tanzania*. BMC Public Health, 2010. **10**: p. 291.
253. Asiimwe-Okiror, G., et al., *Change in sexual behaviour and decline in HIV infection among young pregnant women in urban Uganda*. AIDS, 1997. **11**(14): p. 1757-63.
254. Weller, S.C., *A meta-analysis of condom effectiveness in reducing sexually transmitted HIV*. Soc Sci Med, 1993. **36**(12): p. 1635-44.
255. Hoffman, S., et al., *The future of the female condom*. Int Fam Plan Perspect, 2004. **30**(3): p. 139-45.
256. Abdool Karim, Q., et al., *Effectiveness and safety of tenofovir gel, an antiretroviral microbicide, for the prevention of HIV infection in women*. Science, 2010. **329**(5996): p. 1168-74.

257. Bailey, R.C., et al., *Male circumcision for HIV prevention in young men in Kisumu, Kenya: a randomised controlled trial*. *Lancet*, 2007. **369**(9562): p. 643-56.
258. Gray, R.H., et al., *Male circumcision for HIV prevention in men in Rakai, Uganda: a randomised trial*. *Lancet*, 2007. **369**(9562): p. 657-66.
259. Rechel, B., *HIV/AIDS in the countries of the former Soviet Union: societal and attitudinal challenges*. *Cent Eur J Public Health*, 2010. **18**(2): p. 110-5.
260. Taran, Y.S., et al., *Correlates of HIV risk among injecting drug users in sixteen Ukrainian cities*. *AIDS Behav*, 2011. **15**(1): p. 65-74.
261. Islam, M., A. Wodak, and K.M. Conigrave, *The effectiveness and safety of syringe vending machines as a component of needle syringe programmes in community settings*. *Int J Drug Policy*, 2008. **19**(6): p. 436-41.
262. Kerr, T., et al., *Syringe sharing and HIV incidence among injection drug users and increased access to sterile syringes*. *Am J Public Health*, 2010. **100**(8): p. 1449-53.
263. Des Jarlais, D.C., K. Arasteh, and S.R. Friedman, *HIV among drug users at Beth Israel Medical Center, New York City, the first 25 years*. *Subst Use Misuse*, 2011. **46**(2-3): p. 131-9.
264. Ministry of Health and Social Welfare, T., *Guidelines on the clinical use of blood and blood products, 2006*.
265. Grosskurth, H., et al., *Impact of improved treatment of sexually transmitted diseases on HIV infection in rural Tanzania: randomised controlled trial*. *Lancet*, 1995. **346**(8974): p. 530-6.
266. Grosskurth, H., et al., *Operational performance of an STD control programme in Mwanza Region, Tanzania*. *Sex Transm Infect*, 2000. **76**(6): p. 426-36.
267. Orroth, K.K., et al., *Syndromic treatment of sexually transmitted diseases reduces the proportion of incident HIV infections attributable to these diseases in rural Tanzania*. *AIDS*, 2000. **14**(10): p. 1429-37.
268. Roehr, B., *Tenofovir works as pre-exposure prophylaxis against HIV, two studies confirm*. *BMJ*, 2011. **343**: p. d4540.
269. Bailey, A.C. and M. Fisher, *Current use of antiretroviral treatment*. *Br Med Bull*, 2008. **87**: p. 175-92.
270. Cardo, D.M. and D.M. Bell, *Bloodborne pathogen transmission in health care workers. Risks and prevention strategies*. *Infect Dis Clin North Am*, 1997. **11**(2): p. 331-46.
271. Mephram, S.O., R.M. Bland, and M.L. Newell, *Prevention of mother-to-child transmission of HIV in resource-rich and -poor settings*. *BJOG*, 2011. **118**(2): p. 202-18.
272. Fowler, M.G., J. Bertolli, and P. Nieburg, *When is breastfeeding not best? The dilemma facing HIV-infected women in resource-poor settings*. *JAMA*, 1999. **282**(8): p. 781-3.
273. Dabis, F., et al., *6-month efficacy, tolerance, and acceptability of a short regimen of oral zidovudine to reduce vertical transmission of HIV in breastfed children in Cote d'Ivoire and Burkina Faso: a double-blind placebo-controlled multicentre trial*. *DITRAME Study Group. DIminution de la Transmission Mere-Enfant*. *Lancet*, 1999. **353**(9155): p. 786-92.
274. Fowler, M.G., et al., *Reducing the risk of mother-to-child human immunodeficiency virus transmission: past successes, current progress and challenges, and future directions*. *Am J Obstet Gynecol*, 2007. **197**(3 Suppl): p. S3-9.
275. Coutsoydis, A., L. Kwaan, and M. Thomson, *Prevention of vertical transmission of HIV-1 in resource-limited settings*. *Expert Rev Anti Infect Ther*, 2010. **8**(10): p. 1163-75.
276. Hanke, T., et al., *Clinical experience with plasmid DNA- and modified vaccinia virus Ankara-vectored human immunodeficiency virus type 1 clade A vaccine focusing on T-cell induction*. *J Gen Virol*, 2007. **88**(Pt 1): p. 1-12.
277. Fast, P.E. and P. Kaleebu, *HIV vaccines: current status worldwide and in Africa*. *AIDS*, 2010. **24 Suppl 4**: p. S50-60.

278. Paris, R.M., et al., *Prime-boost immunization with poxvirus or adenovirus vectors as a strategy to develop a protective vaccine for HIV-1*. *Expert Rev Vaccines*, 2010. **9**(9): p. 1055-69.
279. Pantaleo, G., et al., *Poxvirus vector-based HIV vaccines*. *Curr Opin HIV AIDS*, 2010. **5**(5): p. 391-6.
280. Girard, M.P., et al., *Human immunodeficiency virus (HIV) immunopathogenesis and vaccine development: A review*. *Vaccine*, 2011. **29**(37): p. 6191-218.
281. Walker, B.D. and D.R. Burton, *Toward an AIDS vaccine*. *Science*, 2008. **320**(5877): p. 760-4.
282. Rerks-Ngarm, S., et al., *Vaccination with ALVAC and AIDSVAX to prevent HIV-1 infection in Thailand*. *N Engl J Med*, 2009. **361**(23): p. 2209-20.
283. Makedonas, G. and M.R. Betts, *Living in a house of cards: re-evaluating CD8+ T-cell immune correlates against HIV*. *Immunol Rev*, 2011. **239**(1): p. 109-24.
284. Letvin, N.L., et al., *Immune and Genetic Correlates of Vaccine Protection Against Mucosal Infection by SIV in Monkeys*. *Sci Transl Med*, 2011. **3**(81): p. 81ra36.
285. IAVI, *IAVIReport. The publication on AIDS vaccine research*. 2011. p. 1-20.
286. Excler, J.L. and S. Plotkin, *The prime-boost concept applied to HIV preventive vaccines*. *AIDS*, 1997. **11 Suppl A**: p. S127-37.
287. Dolin, R., et al., *The safety and immunogenicity of a human immunodeficiency virus type 1 (HIV-1) recombinant gp160 candidate vaccine in humans*. *NIAID AIDS Vaccine Clinical Trials Network*. *Ann Intern Med*, 1991. **114**(2): p. 119-27.
288. Joseph, J., et al., *A safe, effective and affordable HIV vaccine--an urgent global need*. *AIDS Rev*, 2005. **7**(3): p. 131-8.
289. Mascola, J.R., et al., *Immunization with envelope subunit vaccine products elicits neutralizing antibodies against laboratory-adapted but not primary isolates of human immunodeficiency virus type 1*. *The National Institute of Allergy and Infectious Diseases AIDS Vaccine Evaluation Group*. *J Infect Dis*, 1996. **173**(2): p. 340-8.
290. Gilbert, P.B., et al., *Correlation between immunologic responses to a recombinant glycoprotein 120 vaccine and incidence of HIV-1 infection in a phase 3 HIV-1 preventive vaccine trial*. *J Infect Dis*, 2005. **191**(5): p. 666-77.
291. Flynn, N.M., et al., *Placebo-controlled phase 3 trial of a recombinant glycoprotein 120 vaccine to prevent HIV-1 infection*. *J Infect Dis*, 2005. **191**(5): p. 654-65.
292. Pitisuttithum, P., et al., *Randomized, double-blind, placebo-controlled efficacy trial of a bivalent recombinant glycoprotein 120 HIV-1 vaccine among injection drug users in Bangkok, Thailand*. *J Infect Dis*, 2006. **194**(12): p. 1661-71.
293. Mugerwa, R.D., et al., *First trial of the HIV-1 vaccine in Africa: Ugandan experience*. *BMJ*, 2002. **324**(7331): p. 226-9.
294. Cao, H., et al., *Immunogenicity of a recombinant human immunodeficiency virus (HIV)-canarypox vaccine in HIV-seronegative Ugandan volunteers: results of the HIV Network for Prevention Trials 007 Vaccine Study*. *J Infect Dis*, 2003. **187**(6): p. 887-95.
295. Belshe, R.B., et al., *Safety and immunogenicity of a canarypox-vectored human immunodeficiency virus Type 1 vaccine with or without gp120: a phase 2 study in higher- and lower-risk volunteers*. *J Infect Dis*, 2001. **183**(9): p. 1343-52.
296. Nitayaphan, S., et al., *Safety and immunogenicity of an HIV subtype B and E prime-boost vaccine combination in HIV-negative Thai adults*. *J Infect Dis*, 2004. **190**(4): p. 702-6.
297. Karnasuta, C., et al., *Antibody-dependent cell-mediated cytotoxic responses in participants enrolled in a phase I/II ALVAC-HIV/AIDSVA B/E prime-boost HIV-1 vaccine trial in Thailand*. *Vaccine*, 2005. **23**(19): p. 2522-9.
298. Amara, R.R., et al., *Control of a mucosal challenge and prevention of AIDS by a multiprotein DNA/MVA vaccine*. *Science*, 2001. **292**(5514): p. 69-74.
299. Letvin, N.L., et al., *Preserved CD4+ central memory T cells and survival in vaccinated SIV-challenged monkeys*. *Science*, 2006. **312**(5779): p. 1530-3.

300. Wilson, N.A., et al., *Vaccine-induced cellular responses control simian immunodeficiency virus replication after heterologous challenge*. J Virol, 2009. **83**(13): p. 6508-21.
301. Hansen, S.G., et al., *Effector memory T cell responses are associated with protection of rhesus monkeys from mucosal simian immunodeficiency virus challenge*. Nat Med, 2009. **15**(3): p. 293-9.
302. Lisziewicz, J., S.A. Calarota, and F. Lori, *The potential of topical DNA vaccines adjuvanted by cytokines*. Expert Opin Biol Ther, 2007. **7**(10): p. 1563-74.
303. Graham, B.S., et al., *Phase I safety and immunogenicity evaluation of a multiclade HIV-1 DNA candidate vaccine*. J Infect Dis, 2006. **194**(12): p. 1650-60.
304. Sandstrom, E., et al., *Broad immunogenicity of a multigene, multiclade HIV-1 DNA vaccine boosted with heterologous HIV-1 recombinant modified vaccinia virus Ankara*. J Infect Dis, 2008. **198**(10): p. 1482-90.
305. Luckay, A., et al., *Effect of plasmid DNA vaccine design and in vivo electroporation on the resulting vaccine-specific immune responses in rhesus macaques*. J Virol, 2007. **81**(10): p. 5257-69.
306. Goonetilleke, N., et al., *Induction of multifunctional human immunodeficiency virus type 1 (HIV-1)-specific T cells capable of proliferation in healthy subjects by using a prime-boost regimen of DNA- and modified vaccinia virus Ankara-vectored vaccines expressing HIV-1 Gag coupled to CD8+ T-cell epitopes*. J Virol, 2006. **80**(10): p. 4717-28.
307. Goepfert, P.A., et al., *Phase I safety and immunogenicity testing of DNA and recombinant modified vaccinia Ankara vaccines expressing HIV-1 virus-like particles*. J Infect Dis, 2011. **203**(5): p. 610-9.
308. McCormack, S., et al., *EV02: a Phase I trial to compare the safety and immunogenicity of HIV DNA-C prime-NYVAC-C boost to NYVAC-C alone*. Vaccine, 2008. **26**(25): p. 3162-74.
309. Harari, A., et al., *An HIV-1 clade C DNA prime, NYVAC boost vaccine regimen induces reliable, polyfunctional, and long-lasting T cell responses*. J Exp Med, 2008. **205**(1): p. 63-77.
310. Kibuuka, H., et al., *A phase 1/2 study of a multiclade HIV-1 DNA plasmid prime and recombinant adenovirus serotype 5 boost vaccine in HIV-Uninfected East Africans (RV 172)*. J Infect Dis, 2010. **201**(4): p. 600-7.
311. Buchbinder, S.P., et al., *Efficacy assessment of a cell-mediated immunity HIV-1 vaccine (the Step Study): a double-blind, randomised, placebo-controlled, test-of-concept trial*. Lancet, 2008. **372**(9653): p. 1881-93.
312. McElrath, M.J., et al., *HIV-1 vaccine-induced immunity in the test-of-concept Step Study: a case-cohort analysis*. Lancet, 2008. **372**(9653): p. 1894-905.
313. D'Souza, M.P. and N. Frahm, *Adenovirus 5 serotype vector-specific immunity and HIV-1 infection: a tale of T cells and antibodies*. AIDS, 2010. **24**(6): p. 803-9.
314. Gray, G., S. Buchbinder, and A. Duerr, *Overview of STEP and Phambili trial results: two phase IIb test-of-concept studies investigating the efficacy of MRK adenovirus type 5 gag/pol/nef subtype B HIV vaccine*. Curr Opin HIV AIDS, 2010. **5**(5): p. 357-61.
315. HVTN505, At <http://clinicaltrials.gov/ct2/show/NCT00865566>.
316. Letvin, N.L., *Virology. Moving forward in HIV vaccine development*. Science, 2009. **326**(5957): p. 1196-8.
317. Svahn, A., et al., *Development and evaluation of a flow-cytometric assay of specific cell-mediated immune response in activated whole blood for the detection of cell-mediated immunity against varicella-zoster virus*. J Immunol Methods, 2003. **277**(1-2): p. 17-25.
318. Montefiori, D.C., *Evaluating neutralizing antibodies against HIV, SIV and SHIV in luciferase reporter gene assays*. Current Protocol Immunology, 2004. **Chapter 12**: p. Unit 11-12.
319. Edmonds, T.G., et al., *Replication competent molecular clones of HIV-1 expressing Renilla luciferase facilitate the analysis of antibody inhibition in PBMC*. Virology, 2010. **408**(1): p. 1-13.

320. Shafer, R.W. and T.C. Merigan, *HIV virology for clinical trials*. AIDS, 1995. **9 Suppl A**: p. S193-202.
321. Bredberg Raden, U., *Detection of HIV infection, especially in Africa*. In PhD thesis Karolinska Institute, Swedish Institute for infectious disease control, 1994.
322. Shima-Sano, T., et al., *A human immunodeficiency virus screening algorithm to address the high rate of false-positive results in pregnant women in Japan*. PLoS One, 2010. **5**(2): p. e9382.
323. Miedouge, M., et al., *Analytical sensitivity of four HIV combined antigen/antibody assays using the p24 WHO standard*. J Clin Virol, 2011. **50**(1): p. 57-60.
324. Beelaert, G. and K. Fransen, *Evaluation of a rapid and simple fourth-generation HIV screening assay for qualitative detection of HIV p24 antigen and/or antibodies to HIV-1 and HIV-2*. J Virol Methods, 2010. **168**(1-2): p. 218-22.
325. Olemukan, R.E., et al., *Quality monitoring of HIV-1-infected and uninfected peripheral blood mononuclear cell samples in a resource-limited setting*. Clin Vaccine Immunol, 2010. **17**(6): p. 910-8.
326. Fuss, I.J., et al., *Isolation of whole mononuclear cells from peripheral blood and cord blood*. Curr Protoc Immunol, 2009. **Chapter 7**: p. Unit7 1.
327. Lyons, A.B., *Divided we stand: tracking cell proliferation with carboxyfluorescein diacetate succinimidyl ester*. Immunol Cell Biol, 1999. **77**(6): p. 509-15.
328. Fulcher, D. and S. Wong, *Carboxyfluorescein succinimidyl ester-based proliferative assays for assessment of T cell function in the diagnostic laboratory*. Immunol Cell Biol, 1999. **77**(6): p. 559-64.
329. Quah, B.J. and C.R. Parish, *The use of carboxyfluorescein diacetate succinimidyl ester (CFSE) to monitor lymphocyte proliferation*. J Vis Exp, 2010(44).
330. Godoy-Ramirez, K., et al., *Comparison of three lymphoproliferation assays to monitor HIV-specific T-cell responses in vaccinees immunized with HIV-1 DNA vaccine and HIV-1 MVA*. Poster abstract no. P17.08. AIDS vaccine 2010 conference, Atlanta, USA, 28 September – 1 October 2010. AIDS Res Hum Retroviruses, 2010. **26**(10): p. A-1-A-108. Doi:10.1089/aid.2010.9998.
331. Bakari, M., et al., *The prevalence and incidence of HIV-1 infection and syphilis in a cohort of police officers in Dar es Salaam, Tanzania: a potential population for HIV vaccine trials*. AIDS, 2000. **14**(3): p. 313-20.
332. Aboud, S., et al., *Broad and strong immune responses in a trial of a heterologous DNA prime MVA boost HIV vaccine among healthy Tanzanian volunteers*. Oral abstract no. OA03.07. AIDS vaccine 2010 conference, Atlanta, USA, 28 September – 1 October 2010. AIDS Res Hum Retroviruses, 2010. **26**(10): p. A-1-A-184. Doi:10.1089/aid.2010.9998.
333. Brown, B.K., et al., *Biologic and genetic characterization of a panel of 60 human immunodeficiency virus type 1 isolates, representing clades A, B, C, D, CRF01\_AE, and CRF02\_AG, for the development and assessment of candidate vaccines*. J Virol, 2005. **79**(10): p. 6089-101.
334. Choudhry, V., et al., *Cross-reactive HIV-1 neutralizing monoclonal antibodies selected by screening of an immune human phage library against an envelope glycoprotein (gp140) isolated from a patient (R2) with broadly HIV-1 neutralizing antibodies*. Virology, 2007. **363**(1): p. 79-90.
335. Polonis, V.R., et al., *Recent advances in the characterization of HIV-1 neutralization assays for standardized evaluation of the antibody response to infection and vaccination*. Virology, 2008. **375**(2): p. 315-20.